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Histones undergo different types of post-translational modifications that have been linked 
to a variety of biological processes and disease states. Histone acetylation and 
methylation are well characterized modifications with respect to regulation of chromatin 
structure and transcription. Histone acetylation, regulated by histone acetyltransferases 
(HATs) and histone deacetylases (HDACs), is linked with gene activation. Here we 
introduce a novel paradigm suggesting that holocarboxylase synthetase (HLCS), the sole 
biotin protein ligase in the human genome, recruits nuclear receptor corepressor (N-CoR) 
and HDAC1 to chromatin, thereby contributing toward the removal of lysine (K)-9 
acetylated histone H3 (H3K9ac) gene activation marks and the repression of repeats, 
linking biotin metabolism with histone acetylation. We observed that (1) HLCS interacts 
physically with N-CoR and HDAC1; (2) HLCS overexpression induces a significant 
decrease in the abundance of H3K9ac marks in long terminal repeats (LTRs) 15 and 22 
decreasing LTR expression; and (3) HLCS-dependent repression of pericentromeric 
 
 
alpha satellite repeats. We conclude that interactions of HLCS with N-CoR and HDAC1 
contribute toward transcriptional repression of repeats. Unlike histone acetylation, 
histone methylation is commonly associated with either transcriptional activation or 
repression and is regulated by the opposing activities of histone methyltransferases and 
demethylases. Lysine specific demethylase 1 (LSD1) is a flavin adenine dinucleotide 
(FAD)-dependent demethylase that catalyzes the removal of methyl groups from lysine-4 
in histone H3 (H3K4me1, H3K4me2), thereby mediating gene repression. We cultured 
cells in riboflavin-defined media providing riboflavin at levels representing moderately 
deficient, sufficient, and supplemented in humans. LSD1 activity depends on the 
concentrations of the FAD precursor, riboflavin, in cell culture media, and riboflavin 
deficiency causes de-repression of albumin and pro-inflammatory cytokines in human 
HepG2 and Jurkat cells, respectively. Loss of LSD1 activity is associated with a 
significant increase in the abundance of H3K4me2 marks, leading to an aberrant up-
regulation of target gene expression. In conclusion, riboflavin affects gene regulation by 
epigenetic mechanisms, mediated by a loss of LSD1 activity. 
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INTRODUCTION 
Eukaryotic cells contain largely identical genetic information encoded in DNA. However, 
cells with identical genomes have widely different gene expression patterns in different 
organs and tissues, which need to respond to developmental and environmental changes. 
In eukaryotes, the chromatin state, the packaging of DNA with histone proteins, is 
believed to contribute to the control of gene expression (Jenuwein and Allis, 2001; Greer 
and Shi, 2012). Since the early 1960s, it has been know that histones are post-
translationally modified (Allfrey et al., 1964). Histones are subject to a wide variety of 
post-translational modifications, including but not limited to, lysine acetylation, lysine 
and arginine methylation, serine and threonine phosphorylation, and lysine ubiquitination 
and sumoylation (Vaquero et al., 2003; Tan et al., 2011). These modifications occur 
primarily within the histone amino-terminal tails protruding from the surface of the 
nucleosome as well as on the globular core region (Cosgrove et al., 2004). Histone 
modifications are thought to contribute to the control of gene expression not only through 
regulating chromatin structure by merely being there, but also recruiting remodeling 
enzymes that utilize the energy derived from the hydrolysis of ATP to reposition 
nucleosomes. The recruitment of proteins and complexes with specific enzymatic 
activities is now an accepted dogma of how modifications mediate their function (Strahl 
and Allis, 2000; Bannister and Kouzarides, 2011).  
Histone acetylation, first discovered in 1964 (Allfrey et al., 1964), is a dynamic post-
translational modification regulated by the opposing activities of histone 
acetyltransferases (HATs) and histone deacetylases (HDACs) (Shahbazian and Grunstein, 
2007). Aacetylation catalyzed by HATs usually marks transcriptionally active genes, as it 
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contributes to the decondensed chromatin state and maintains the unfolded structure of 
the transcribed nucleosome (Tse et al., 1998; Wang et al., 2001; Shogren-Knaak et al., 
2006; Shahbazian and Grunstein, 2007; Davie et al., 2008). In contrast, HDACs are found 
in corepressor complexes catalyzing deacetylation of histones, leading to the  formation 
of a compacted, transcriptionally repressed chromatin structure (Yang and Seto, 2007). 
To date, eighteen different mammalian HDACs have been identified and divided into 
four classes based on their sequence similarity to yeast counterparts. HDACs from the 
classical family are dependent on Zn2+ for deacetylase activity and constitute classes I, II 
and IV. Classes I and II contain enzymes that are most closely related to yeast scRpd3 
and scHda1, respectively. Class IV has only a single member, HDAC11, while class III 
(sirtuins) are homologous to yeast scSir2. Class III HDACs, in contrast to the other three 
classes, requires a specific cofactor, NAD+, for catalytic activity (de Ruijter et al., 2003; 
Gregoretti et al., 2004; Yang and Seto, 2007). 
In general, HDACs have relatively low substrate specificity if operating independently of 
other proteins, and may deacetylate multiple lysine residues in histones. HDACs are 
typically present in multiple distinct complexes. For instance, HDAC1 is found together 
with HDAC2 in multiprotein corepressor complexes Sin3, nucleosome-remodeling 
HDAC (NuRD) and CoREST, which are recruited to chromatin regulatory regions by 
transcription factors and play very diverse, often cell-specific, roles (de Ruijter et al., 
2003; Yang and Seto, 2008; Patel et al., 2011). The interactions among these proteins in a 
complex likely determine the overall activity, substrate specificity and genomic location 
of the multiprotein complex. Of note, HDAC1 and HDAC2 also interact with nuclear 
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receptor corepressor (N-CoR) through the most N-terminal of N-CoR repression domain 
via the Sin3 corepressor (Alland et al., 1997; Heinzel et al., 1997; Nagy et al., 1997). 
Histone methylation, mainly occurring on the side chains of lysines (K) and arginines (R),  
has a long half-life compared to other histone modifications (Barth and Imhof, 2010). 
Unlike histone acetylation, which is always associated with transcriptional activation 
(Grunstein, 1997), histone methylation can be involved in either transcriptional activation 
or repression. For example, K4-dimethylated histone H3 (H3K4me2) is an active mark 
for transcription. In contrast, K9-trimethylated histone H3 (H3K9me3) is linked to 
transcriptional repression (Allis et al., 2007; Kouzarides, 2007). Histone methylation, 
catalyzed by histone methyltransferases (Petrossian and Clarke, 2011), was originally 
thought to be relatively permanent and irreversible (Byvoet et al., 1972). That paradigm 
changed with the discovery of the first histone demethylase, lysine specific demethylase 
1 (LSD1; also known as KDM1A, BHC110 and AOF2). It is now widely accepted that 
histone methylation is, in fact, reversible (Shi et al., 2004). Both histone 
methyltransferases and demethylases have central roles in various cell biological 
processes, including regulation of chromatin structure and transcription; they are also 
important for normal development and are involved in diseases such as cancer (Pedersen 
and Helin, 2010; Duncan and Allis, 2011; Yoshimi and Kurokawa, 2011). Genetic studies 
have shown that deletion or mutation of several different demethylases lead to 
developmental defects (Pedersen and Helin, 2010). For example, deletion or mutation of 
LSD1 homologues in Drosophila melanogaster and Caenorhabiditis elegans affects the 
germ line and fertility in both organisms (Di Stefano et al., 2007; Katz et al., 2009; 
Eliazer et al., 2011). 
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LSD1 catalyzes the removal of methyl groups from K4-monomethylated histone H3 
(H3K4me1) and H3K4me2 via a flavin adenosine dinucleotide (FAD)-monoamine 
oxidase mechanism (Shi et al., 2004; Forneris et al., 2005; Lee et al., 2005; Rudolph et al., 
2007). Consistent with the H3K4me1/2 activation mark as a substrate, LSD1 is found in 
cells as part of a complex with the co-repressor, CoREST and HDAC1/2 (Humphrey et 
al., 2001; You et al., 2001; Hakimi et al., 2002), which represses transcription by 
deacetylating histone tails. Besides these canonical functions, LSD1 has also been 
identified as a component of NuRD complex, via interaction of the Tower domain with 
metastasis tumor antigen 1-3 in breast cancer cells (Wang et al., 2009). Interestingly, the 
demethylase specificity and activity of LSD1 appear to be determined by its binding 
partners. When associated with the androgen receptor, LSD1 switch its substrate 
specificity from H3K4me1/2 to H3K9me1/2 (Metzger et al., 2005; Wissmann et al., 
2007), consistent with a role in gene activation (Garcia-Bassets et al., 2007). Thus, the 
composition of LSD1-containing complexes has the potential to alter the substrate 
specificity. 
This introduction will focus on the regulation of gene expression through histone 
modifications from the following two perspectives: one is the role of K9-acetylated 
histone H3 (H3K9ac) marks in the repression of repeats, as mediated by physical 
interactions between holocarboxylase synthetase (HLCS) and N-CoR and HDAC1; the 
other is the role of H3K4me2 marks in the expression of target genes, mediated by the 
FAD-dependent LSD1 in cell cultures. 
HLCS represses gene expression through a multi-protein complex 
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Biotin is a water-soluble vitamin that serves as a covalently bound coenzyme for five 
carboxylases (Zempleni et al., 2012b). HLCS catalyzes the binding of biotin to all five 
carboxylases and, therefore, plays a pivotal role in biotin-dependent metabolic pathways 
(Suzuki et al., 1994; Zempleni et al., 2012b). Recently, it was demonstrated that HLCS 
participates in gene regulation at the chromatin level, i.e., full-length HLCS and a 
splicing variant enter the nuclear compartment and bind to chromosomes in a locus-
specific, punctuate pattern (Camporeale et al., 2006b; Singh et al., 2011). Evidence 
suggests that HLCS also has histone-biotin ligase activity (Kobza et al., 2008; Bao et al., 
2010), catalyzing the covalent binding of biotin to distinct lysine residues in histones 
(H2A, H3, and H4), and HLCS knock-down leads to a loss of biotinylation marks on 
histones (Camporeale et al., 2004; Kobza et al., 2005; Chew et al., 2006; Chew et al., 
2008; Bao et al., 2011; Pestinger et al., 2011; Rios-Avila et al., 2012).  
Consistent with the important roles of HLCS in intermediary metabolism, no living 
HLCS null individual has ever been reported, suggesting embryonic lethality. Mutations 
of human HLCS gene have been identified and characterized, which cause a substantial 
decrease in HLCS activity and metabolic abnormalities (Suzuki et al., 2005). HLCS 
knockdown results in severe phenotypes such as short life span and low heat stress 
resistance in Drosophila melanogaster and chromosomal abnormalities in human cell 
cultures (Camporeale et al., 2006a; Chew et al., 2008).  
Recently, a coherent model has been established, which implicates HLCS in gene 
repression through epigenetic mechanisms (Fig. 1). In this model, HLCS locates to the 
chromatin through physical interactions with DNA methyltransferase 1 and methyl CpG 
binding protein 2 (Xue et al., 2013) and this chromatin-bound HLCS further recruits 
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eukaryotic histone H3 methyltransferase 1 (EHMT-1) , which creates abundant K9-
dimethylated histone H3 (H3K9me2) repression marks and mediates repression (Li et al., 
2013). According to this model, histone biotinylation is considered as mere marks for 
HLCS docking sites in chromatin and is caused by the close physical proximity between 
HLCS and histones (Bao et al., 2011). Notably, histone biotinylation is a comparably rare 
modification, only less than 0.001% of histones H3 and H4 being biotinylated in human 
chromatin (Stanley et al., 2001; Bailey et al., 2008; Kuroishi et al., 2011). However, the 
abundance of an epigenetic mark is not the measure for its importance and this novel 
model may explain the controversies between the rarity of histone biotinylation and its 
significance in metabolism. 
 
Figure 1 HLCS-containing multi-protein gene repression complex. 
DNA methylation in the genome is maintained by DNMT1, which recruits MeCP2 to 
bind to methylated CpG. HLCS locates to the same loci through physical interactions 
with MeCP2 and DNMT1, and further recruits EHMT1, N-CoR, and HDACs. 
Abbreviations: ac, acetyl; bio, biotin; DNMT1, DNA methyl transferase 1; HP1, 
heterochromatin protein 1; MBD, methyl-binding domain proteins; me, methyl; MeCP2, 
methyl-CpG-binding protein 2 (Liu, et al., unpublished). 
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Biotinylation marks have been linked to gene repression due to the fact that they are 
enriched in repressed genomic loci and found to co-localize with the repressive histone 
methylation marks (Camporeale et al., 2007; Chew et al., 2008; Gralla et al., 2008; 
Wijeratne et al., 2010; Pestinger et al., 2011; Rios-Avila et al., 2012; Li et al., 2013). For 
example, K12-biotinylated histone H4 (H4K12bio) is a mark for repeat regions and 
heterochromatin, plays a role in gene repression, and co-localizes with the repression 
mark H3K9me2 (Camporeale et al., 2007). Furthermore, the correlation between histone 
biotinylation and the repression of long terminal repeats (LTRs) in the human genome 
has been reported in previous studies (Zempleni et al., 2009). Chromatin 
immunoprecipitation assays provided evidence that H4K12bio is greatly enriched at loci 
coding for both intact and solitary LTRs in a human lymphoid cell line. Similar 
observations were made in human and mouse cell lines that originated in other tissues 
(Chew et al., 2008). HLCS dysfunction caused by genetic deficiency was correlated with 
increased transcription level of LTRs (Chew et al., 2008). These observations have 
substantial biological importance because transcription of LTRs is the first and critical 
step in retrotransposition events, which further increase the rates for spontaneous 
mutations in the genome  (Kazazian, 2004; Martens et al., 2005; Kovalskaya et al., 2006; 
Slotkin and Martienssen, 2007; Zempleni et al., 2009). A great variety of human diseases 
have been linked to retrotranspositions in the genome, including breast cancer and colon 
cancer (Kazazian et al., 1988; Morse et al., 1988; Miki et al., 1992). 
LSD1 regulates gene expression depending on riboflavin supply 
Riboflavin, a water-soluble vitamin, is a precursor of FAD and flavin mononucleotide 
(FMN), which function as coenzymes for redox reactions in numerous metabolic 
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pathways and in energy production (Rivlin, 1986; Rivlin, 2001). The redox reactions in 
which flavocoenzymes participate include flavoprotein-catalyzed dehydrogenations, 
reactions with sulfur-containing compounds, hydroxylations, oxidative decarboxylations, 
dioxygenations, and reduction of oxygen to hydrogen peroxide (National, 1998). 
Riboflavin metabolism begins with the adenosine triphosphate-dependent 
phosphorylation of riboflavin to FMN. FMN can then be complexed with specific 
apoenzymes to form a variety of flavoproteins; however, most FMN is converted to FAD 
and the latter is the predominant flavocoenzyme in body tissues (National, 1998).  
Maternal intake of riboflavin has been shown to correlate positively with fetal growth and 
development (Badart-Smook et al., 1997). Animal studies suggest that riboflavin 
deficiency during pregnancy leads to congenital abnormalities (Rivlin, 1975). The signs 
of riboflavin deficiency in humans include sore throat, hyperemia of oral mucous 
membranes, normocytic anemia associated with pure erythrocyte cytoplasia of the bone 
marrow, and other physical symptoms (Powers, 2003). Severe riboflavin deficiency may 
impair the metabolism of vitamin B6 by limiting the amount of FMN required by 
pyridoxine 5-phosphate oxidase and the conversion of tryptophan to functional forms of 
niacin (McCormick, 1989). 
Previous studies in cell models suggested that riboflavin deficiency impairs the oxidative 
folding and secretion of interleukin (IL)-2 in human T lymphoma Jurkat cells, as well as 
secretion of apolipoprotein B-100 in HepG2 human hepatocarcinoma cells (Camporeale 
and Zempleni, 2003; Manthey et al., 2005). In addition, riboflavin deficiency has been 
correlated to oxidative damage to proteins and DNA in HepG2 cells (Manthey et al., 
2006).  
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It is widely recognized that nutritional factor play a role in methylation events, although 
the majority of previous studies focused on methyl donors (Zempleni et al., 2012a). 
LSD1, known as the first reported histone demethylase, is unique among numerous 
histone demethylases due to its dependence on FAD (Forneris et al., 2005). To date, there 
is no published research focusing on the effects of riboflavin supply on LSD1 
demethylase activity. This knowledge gap caused concern since riboflavin deficiency 
could be caused by multiple factors, such as genetic abnormalities, thyroid hormone 
insufficiency, alcohol consumption, and consumption of certain drugs, e.g., tricyclic and 
tetracyclic compounds (Pinto et al., 1981; Cimino et al., 1987; Pinto et al., 1987; Dutta et 
al., 1988; Horvath, 2012).  
Conclusion 
Histone modifications, believed to be implicated in the epigenetic regulation of gene 
expression, are not only affected by the synergized chromatin proteins, but also impacted 
by the supply of nutrients. The following chapters will provide in-depth investigations of 
the underlying mechanism of the (i) HLCS-containing protein complex in repression of 
repeats; (ii) FAD-dependent LSD1 activity and target gene expression, and (iii) FAD-
dependent LSD1 in the regulation of pro-inflammatory cytokine expression. 
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Abstract 
Holocarboxylase synthetase (HLCS) is a nuclear protein that catalyzes the binding of 
biotin to distinct lysine residues in chromatin proteins. HLCS-dependent epigenetic 
marks are overrepresented in repressed genomic loci, particularly in repeats. Evidence is 
mounting that HLCS is a member of a multi-protein gene repression complex, which 
determines its localization in chromatin. Here we tested the hypothesis that HLCS 
interacts physically with nuclear receptor corepressor (N-CoR) and histone deacetylase 1 
(HDAC1), thereby contributing toward the removal of lysine-9 acetylated histone H3 
(H3K9ac) gene activation marks and the repression of repeats. Physical interactions 
between HLCS and N-CoR, HDAC1, and a novel splicing variant of HDAC1 were 
confirmed by co-immunoprecipitation, limited proteolysis, and split luciferase 
complementation assays. When HLCS was overexpressed, the abundance of H3K9ac 
marks decreased by 50% and 68% in long terminal repeats (LTRs) 15 and 22, 
respectively, in human embryonic kidney HEK293 cells compared with controls. This 
loss of H3K9ac marks was linked with an 83% decrease in mRNA coding for LTRs. 
Similar patterns were seen in pericentromeric alpha satellite repeats in chromosomes 1 
and 4. We conclude that interactions of HLCS with N-CoR and HDACs contribute 
toward the transcriptional repression of repeats, presumably increasing genome stability. 
 
Key Words: chromatin; epigenetics; gene repression; holocarboxylase synthetase; histone 
deacetylase 1; nuclear receptor corepressor  
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Introduction 
Holocarboxylase synthetase (HLCS) is the sole biotin protein ligase in the human 
genome (Suzuki et al., 1994). Historically, HLCS was appreciated for its role in attaching 
biotin to distinct lysine residues in five human carboxylases, which catalyze essential 
steps in fatty acid metabolism, gluconeogenesis, and leucine metabolism in cytoplasm 
and mitochondria (Zempleni et al., 2012). Recently, it was demonstrated that full-length 
HLCS and a splicing variant also enter the nuclear compartment and that nuclear HLCS 
binds to chromosomes in a locus-specific, punctuate pattern (Camporeale et al., 2006b; 
Singh et al., 2011). These observations implicate HLCS in gene regulation. Unambiguous 
evidence suggests that HLCS has histone-biotin ligase activity (Kobza et al., 2008; Bao et 
al., 2010), catalyzing the binding of biotin to distinct lysine residues in histones 
(Camporeale et al., 2004; Kobza et al., 2005; Chew et al., 2006). HLCS-dependent 
histone biotinylation marks are enriched in repressed genomic loci (Camporeale et al., 
2007a; Chew et al., 2008; Gralla et al., 2008; Wijeratne et al., 2010; Pestinger et al., 
2011; Rios-Avila et al., 2012), consistent with a role of HLCS in gene repression. Note 
that only less than 0.001% of histones H3 and H4 are biotinylated in human chromatin 
(Stanley et al., 2001; Bailey et al., 2008; Kuroishi et al., 2011). Because of the rarity of 
biotinylation marks, it is unlikely that histone biotinylation per se is responsible for 
causing the repression of genes and severe phenotypes of HLCS knockdown such as 
short life span and low heat stress resistance in Drosophila melanogaster and 
chromosomal abnormalities in human cell cultures (Camporeale et al., 2006a; Chew et al., 
2008). Moreover, HLCS does not contain a classical nuclear localization signal or a 
DNA-binding motif that would explain its nuclear localization and binding to 
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chromosomes. Evidence suggest that the binding of HLCS to chromosomes and perhaps 
its nuclear entry might be facilitated by physical interactions with histone H3 (Bao et al., 
2011), but these interactions do not explain the punctuate distribution of HLCS in 
chromatin (Camporeale et al., 2006b; Singh et al., 2011). 
Recently, we have integrated the above reports into a coherent model that implicates 
HLCS in gene repression through epigenetic mechanisms (Fig. 1). According to this 
model, HLCS is recruited to chromatin through physical interactions with the 
maintenance DNA methyltransferase DNMT1 and the methyl CpG binding protein 2, 
MeCP2 (Xue et al., 2013), consistent with previous observations that erasure of DNA 
methylation marks impairs HLCS-dependent biotinylation events in chromatin (Chew et 
al., 2008). Also according to this model, chromatin-bound HLCS recruits the eukaryotic 
histone H3 methyltransferase EHMT-1, which creates abundant lysine-9 methylated 
histone H3(H3K9me) gene repression marks; the physical interaction between HLCS and 
EHMT-1 appears to be strengthened by HLCS-dependent biotinylation of lysine-161 in 
EHMT-1 (Li et al., 2013). Consistent a role of HLCS in the formation of a multi-protein 
gene repression complex, the abundance of H3K9me marks in repeats is severely reduced 
in HLCS knockdown models (Chew et al., 2008; Pestinger et al., 2011). Histone 
biotinylation marks are mere marks for HLCS docking sites in chromatin and are caused 
by the close physical proximity between HLCS and histones (Bao et al., 2011). 
The discovery of the interactions between HLCS and EHMT-1 was initiated by 
developing a protocol for predicting HLCS-binding proteins in silico (Li et al., 2013). 
Note that the protocol also predicted that HLCS interacts with N-CoR, a protein known to 
facilitate the binding of HDACs in chromatin (Alland et al., 1997; Heinzel et al., 1997; 
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Nagy et al., 1997). HDACs play crucial roles in gene repression, mediated by HDAC-
dependent removal of histone acetylation marks (Kouzarides and Berger, 2007).  Here we 
tested the hypotheses that HLCS interacts with N-CoR and HDAC1 and that these 
interactions play roles in the repression of repeats. 
 
Results 
In silico predictions 
In silico predictions suggested that the GGGG(K/R)G(I/M)R sequence in N-CoR is a 
candidate for mediating physical interactions with HLCS and that, because of the known 
interactions between N-CoR and HDAC1, the latter might also be a candidate for 
interacting physically with HLCS. N-CoR had score of 17.2 bits and an E value of 393, 
compared with scores of 20.2 bits and 16.3 bits and E values of 57 and 634 for the 
HLCS-interacting proteins propionyl-CoA carboxylase and EHMT-1, respectively. 
Interaction between HLCS and N-CoR 
HLCS interacts with the C-terminus in N-CoR, based on the following lines of evidence. 
HEK293 cells were co-transfected with plasmid pCMV-Myc-HLCS and plasmids coding 
for the three N-CoR fragments, i.e., pCMV-HA-N-CoR-NT, pCMV-HA-N-CoR-CD, or 
pCMV-HA-N-CoR-CT. When cell lysates were precipitated with anti-Myc and probed 
with anti-HA, a distinct signal was obtained only for cells transfected with the plasmid 
coding for the N-CoR C-terminus, pCMV-HA-N-CoR-CT (Fig. 3A, upper gel), but not 
for those transfected with pCMV-HA-N-CoR-NT and pCMV-HA-N-CoR-CD (data not 
shown). The same pattern was seen when cell lysates were precipitated with anti-HA and 
probed with anti-HLCS (Fig. 3A, lower gel, and data not shown). Empty vectors in 
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various permutations and non-transfected cells produced no detectable signal (negative 
controls). Next, tags were swapped and HEK293 cells were co-transfected with pCMV-
HA-HLCS and either pCMV-Myc-N-CoR-NT, pCMV-Myc-N-CoR-CD, or pCMV-Myc-
N-CoR-CT. Again, only cells co-transfected with HLCS and the plasmid coding for the 
N-CoR C-terminus, pCMV-HA-N-CoR-CT, produced distinct signals in co-
immunoprecipitation assays; no signal was produced by negative controls (Fig. 3B, upper 
and lower gels) and by cells co-transfected with HLCS and plasmids coding for the N-
terminus and central domain in N-CoR (data not shown). 
Previous studies suggest that lysine residues in HLCS-binding motifs are important for 
HLCS binding (Li et al., 2013). The predicted motif in N-CoR includes K2323 and 
K2325 in full-length N-CoR. When HEK293 cells were co-transfected with plasmid 
pCMV-HA-HLCS and plasmids coding for the wild-type C-terminus in N-CoR (pCMV-
Myc-N-CoR-CT), the K2323 mutant (pCMV-Myc-N-CoR-CTK2323R), the K2325 mutant 
(pCMV-Myc-N-CoR-CTK2325R), or the deletion construct (pCMV-Myc-N-CoR-CTdel), 
meaningful signals were detected only for the wild-type N-CoR and the K2323 mutant, 
suggesting that K2325 and the HLCS-binding motif are essential for mediating 
interactions with HLCS (Fig. 3C, upper gel). The same pattern was seen when cell lysates 
were precipitated with anti-HA and probed with anti-Myc (Fig. 3C, lower gel). 
Limited proteolysis assays were conducted using recombinant proteins. When 
recombinant HLCS and the C-terminal fragment of N-CoR were incubated with trypsin 
in the absence of putative binding partners, both proteins degraded completely within 10 
min of incubation (Fig. 3D, upper and middle gels). In contrast, when recombinant HLCS 
was pre-incubated with the N-CoR C-terminal fragment prior to trypsin treatment, the 
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proteolytic degradation of both HLCS and N-CoR was substantially delayed compared 
with the individual proteins, and strong protein signals were detectable after 30 min of 
incubation with trypsin (Fig. 3D, lower gel). When recombinant HLCS was pre-incubated 
with N-CoR N-terminus and central domain, tryptic digestion of the proteins was not 
delayed (data not shown). Note that the molecular weights of recombinant HLCS (~81 
kDa) and the N-CoR C-terminus (~82 kDa) are similar, making it difficult to distinguish 
the two proteins at early time points of incubation (≤20 min), when protein 
concentrations are high.  
Split luciferase complementation assays were conducted to confirm the interactions 
between HLCS and N-CoR fragments. When co-expressed in HEK293 cells, constructs 
HLCS-NLuc and N-CoR-CT-CLuc produced a strong chemiluminescence signal, 
whereas N-CoR-NT-CLuc and N-CoR-CD-CLuc produced a signal that was equivalent 
to the background signal produced by co-expressing N- and C-terminal fragements of 
luciferase not fused to protein (Fig. 4). Positive control (TP53-NLuc plus MDM2-CLuc) 
and negative control (TP53-NLuc plus CDK3-CLuc) produced the expected results. 
Specifically, the signal produced by co-expression of constructs HLCS-NLuc and N-
CoR-CT-CLuc was about 3.7 times the signal produced by cells that were co-transfected 
with unfused NLuc and CLuc fragments (background control for self-association) and 
about 3.1 times the signal produced by cells transfected with TP53-NLuc and CDK3-
CLuc. 
Interactions between HLCS and HDAC1s 
HLCS interacts physically with full-length HDAC1 and the novel splicing variant 
HDAC1Δ31, based on the following lines of evidence. HEK293 cells were co-transfected 
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with pCMV-Myc-HLCS and either pCMV-HA-HDAC1 or pCMV-HA-HDAC1Δ31. 
When cell lysates were precipitated with anti-Myc and probed with anti-HDAC1 
(Abcam), distinct signals were obtained for both HDAC1 and HDAC1Δ31 (Fig. 5A, 
upper gel). Likewise, when cell lysates were precipitated with anti-HA and probed with 
anti-HLCS, distinct signals were obtained for HLCS (Fig. 5A, lower gel). Empty vectors 
in various permutations and non-transfected cells produced no detectable signal (negative 
controls). Next, tags were swapped and HEK293 cells were co-transfected with pCMV-
HA-HLCS and either pCMV-Myc-HDAC1 or pCMV-Myc-HDAC1Δ31. Again, only 
cells co-transfected with HLCS and HDAC1 or HDAC1Δ31produced distinct signals, 
whereas no signal was produced by negative controls (Fig. 5B, upper and lower gels). 
Limited proteolysis assays were conducted with recombinant HLCS and HDAC1s. 
Recombinant HLCS was degraded within 10 min of incubation with trypsin, if no 
HDAC1s was added to the sample. Similarly, HDAC1 and HDAC1Δ31 were completely 
degraded within 20 min of trypsin treatment, if no HLCS was present (Fig. 5C, left gels). 
When recombinant HLCS was pre-incubated with either HDAC1 or HDAC1Δ31 before 
trypsin treatment, the proteolytic degradation of both HDAC1s was substantially delayed 
compared with the individual treatments, and strong protein signals were detectable even 
after 30 min of incubation with trypsin (Fig. 5C, middle and right gels). The proteolytic 
degradation of HLCS was not delayed in samples containing HDAC1s (see Discussion). 
Split luciferase complementation assays confirmed that HLCS interacts with HDAC1s. 
HEK293 cells were co-transfected with constructs HLCS-NLuc and either HDAC1-CLuc 
or HDAC1Δ31-CLuc. Co-expression resulted in a strong chemiluminescence signal for 
both HDAC constructs, which was significantly higher than that of controls (Fig. 6). The 
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signal was about 2.9 times the signal produced by cells that were co-transfected with 
unfused NLuc and CLuc fragments (background control for self-association) and about 
2.4 times the signal produced by cells transfected with TP53-NLuc and CDK3-CLuc 
(negative control). 
The roles of HLCS domains in mediating interactions with N-CoR and HDAC1s 
The N-terminus in HLCS is essential for mediating physical interactions with N-CoR and 
HDAC1s. HEK293 cells were co-transfected with pCMV-Myc constructs coding for the 
four known HLCS domains (Hassan et al., 2009a) and either pCMV-HA-N-CoR-CT, 
pCMV-HA-HDAC1, or pCMV-HA-HDAC1Δ31. When cell lysates were precipitated 
with anti-Myc and probed with anti-HA, distinct signals were obtained only for cells co-
transfected with pCMV-Myc-HLCS-NT and the N-CoR C-terminus or HDAC1 
constructs, but not for cells in which HLCS domains other than the N-terminus were 
overexpressed and also not for the various negative controls (Fig. 7A,B).  
HLCS-dependent biotinylation of N-CoR and HDAC1s 
Recombinant HLCS biotinylates recombinant N-CoR and HDAC1s in vitro, consistent 
with the promiscuous nature of HLCS and its microbial ortholog BirA {(Kobza et al., 
2008; Bao et al., 2011; Li et al., 2013); see Discussion]}. When recombinant HLCS was 
incubated with recombinant N-CoR N-terminus, central domain, and C-terminus for 2 h, 
protein-bound biotin was detected in the N-CoR C-terminus (Fig. 8A, lower gels) but too 
a much lesser extent in the other domains of N-CoR (upper gels) using anti-biotin as 
probe. When recombinant HLCS was incubated with HDAC1 or HDAC1Δ31 for 2 h, 
protein-bound biotin was detected in both HDAC1 and HDAC1Δ31 (Fig. 8B). Negative 
controls were created by omitting HLCS, N-CoR, or HDAC1s in biotinylation assays; the 
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negative produced biotin signals that were negligible or not detectable. Equal loading was 
confirmed using coomassie blue.  
Transcriptional regulation of repeats by HLCS 
The abundance of H3K9ac marks in repeats depended on HLCS in HEK293 cells. HLCS 
was overexpressed using plasmid p3XFLAG-Myc-CMV-26-HLCS (Xue et al., 2013) and 
the efficacy of HLCS overexpression was assessed using mRNA and protein levels. The 
abundance of mRNA coding for HLCS was about 49 times greater in overexpression 
cells compared with non-transfected controls; the increase in protein abundance was 
equally compelling (Fig. 9A and insert). While HLCS overexpression caused no 
meaningful change in the global abundance of H3K9ac marks in whole cell extracts (Fig. 
9A, insert), there was a considerable loss of H3K9ac marks in repeats.  
HLCS overexpression caused a decrease of H3K9ac marks in LTR15, LTR22, 
Chr1alpha, and Chr4alpha compared with HLCS-normal controls (Fig. 9B, including a 
blown up presentation of the Chr1alpha and Chr4alpha data). The decreases amounted to 
the loss of 50%, 68%, 62%, and 50% of H3K9ac marks in LTR15, LTR22, Chr1alpha, 
and Chr4alpha, respectively. The abundance of H3K9ac marks did not change in the 
GAPDH promoter in euchromatin, consistent with a locus-specific effect of HLCS. 
The HLCS-dependent depletion of H3K9ac marks in LTRs caused an 83% decrease in 
the global abundance of mRNA coding for LTRs in HEK293 cells (Fig. 9C), using 
primers that do not distinguish among the transcriptionally active LTR in the human 
genome (Chew et al., 2008). Again, effects of HLCS overexpression on transcriptional 
activity were not specific for LTRs, but were also seen in Chr1alpha andChr4alpha 
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repeats for which the abundance of transcripts decreased by 81% and 82%, respectively, 
compared with HLCS-normal controls. 
 
Discussion 
This is the first report suggesting that HLCS interacts physically with N-CoR and 
HDAC1, thereby promoting the repression of repeats through removing H3K9ac marks. 
This paper supports a model in which HLCS and biotin participate in the repression of 
genes at the epigenetic level through orchestrating the assembly of a multi-protein gene 
repression complex that integrates DNA methylation, histone H3 methylation, and 
histone deacetylation events (Li et al., 2013; Xue et al., 2013). There is high confidence 
that the reported interactions are real, based on the following lines of reasoning. First, the 
interactions reported in this paper are consistent predictions by a protocol for identifying 
HLCS-binding proteins in silico (Li et al., 2013). Second, the in silico predictions were 
validated experimentally using three independent procedures, i.e., co-
immunoprecipitation assays, limited proteolysis assays, and split luciferase 
complementation assays. Third, the interaction between HLCS and the C-terminus in N-
CoR was abrogated when the HLCS-binding motif was altered by point mutation or 
deletion. Fourth, N-CoR C-terminus, HDAC1, and HDAC1Δ31 are targets for 
biotinylation by HLCS in vitro. Fifth, the interactions between HLCS and other 
chromatin proteins is mediated by the HLCS N-terminus, which is also responsible for 
mediating interactions between HLCS and its classical carboxylase substrate (Hassan et 
al., 2009a; Ingaramo and Beckett, 2009). Sixth, overexpression of HLCS causes a 
substantial, locus-specific loss of H3K9ac marks in LTRs and pericentromeric alpha 
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satellite repeats. In addition, this report is consistent with previous studies in healthy 
adults, Drosophila melanogaster, and mammalian cell cultures suggesting that the 
repression of LTRs and select other loci depends on HLCS and biotin (Camporeale et al., 
2007b; Chew et al., 2008; Gralla et al., 2008; Pestinger et al., 2011; Rios-Avila et al., 
2012). 
Based on this report, it is a plausible assumption that loss of HLCS or deficiency of biotin 
may cause a de-repression of repeats, which may impair genome stability. For example, 
LTRs make up about 8% of the human genome and at least 51 LTRs are transcriptionally 
competent (Buzdin et al., 2006). Repetitive elements such as LTRs pose a burden to 
genome stability, as their mobilization facilitates recombination between non-
homologous loci, leading to chromosomal deletions and translocations (Kazazian, 2004; 
Martens et al., 2005). Mobilization of LTR transposons is associated with 10% of all 
spontaneous mutations in mice (Waterston et al., 2002). The transcriptional activity of 
LTRs is controlled by histone acetylation and other epigenetic marks; inhibition of 
HDACs leads to an increase in LTR transcription (Brunmeir et al., 2010). De-repression 
of LTRs may impair genome stability through insertional mutagenesis, recombination 
events that cause translocations and other rearrangements, de-regulation of genes in the 
host genome mediated by LTR promoter activity, and antisense effects if transcription 
extends into exon sequence downstream of the transposon (Yoder et al., 1997). 
Our discovery that N-CoR and HDAC1s are targets for biotinylation of HLCS is also of 
great interest in the field of protein biotinylation. Previous studies suggest that 
biotinylation sites in the histone methyltransferase EHMT-1 are important for 
strengthening HLCS/EHMT-1 interactions (Li et al., 2013). The same appears to be the 
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case for K2325 in N-CoR which was important for mediating HLCS/N-CoR interactions 
in limited proteolysis assays. We are in no position to formally conclude that 
biotinylation of K2325 in N-CoR is important for mediating these interactions, because 
we do not know the exact biotinylation site(s) in N-CoR. However, it is becoming 
increasingly clear that HLCS and its microbial ortholog BirA are fairly promiscuous 
enzymes that catalyze the biotinylation of proteins other than their classical substrates, 
i.e., the five mammalian biotin-dependent carboxylases (Kobza et al., 2008; Bao et al., 
2011; Li et al., 2013). We have discovered 108 novel biotinylated proteins in human cells 
(Li Y et al., submitted), but shall point out that not all lysine-containing peptides and 
proteins are substrates for biotinylation by HLCS (Hassan et al., 2009b), suggesting that 
some of these biotinylation events have biological importance. For example, we have 
recently reported preliminary findings that HLCS biotinylates K10 and K12 in the c-myc 
promoter binding protein MBP-1, and that biotinylation of MBP-1 decreases the 
expression of c-myc and cyclooxygenase 2 oncogenes (Zhou et al., 2013). 
Some uncertainties remain. First, we do not know for certain that biotinylation of N-CoR 
and HDAC1s contributes toward strengthening the binding between HLCS and other 
proteins. Theoretically, it is possible that point mutations and deletion can have the same 
effect without depending on changes in protein biotinylation. Second, the HLCS/HDAC 
interaction caused a considerable decrease in the proteolytic degradation of HDAC1s in 
limited proteolysis assays, but did not slow the degradation of HLCS. We speculate that 
target sites for proteolytic degradation are exposed on the surface of HLCS upon 
interaction with HDAC1s. Unfortunately, no 3-D structures are available for human 
HLCS, making it difficult to test the validity of our speculation. Third, we do not know 
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yet whether HLCS also interacts with HDAC2, which has a high sequence similarity 
compared with HDAC1 (Brunmeir et al., 2009). 
We conclude that HLCS exerts some of its roles in gene regulation through the formation 
of multi-protein gene repression complex in human chromatin. Possible members of this 
complex include proteins involved in DNA methylation, EHMT-1, N-CoR, and HDAC1. 
This model also suggests that the roles of HLCS in metabolism go far beyond that of a 
ligase that attaches biotin to carboxylases. We are currently in the process of creating an 
HLCS knockout mouse model that will allow us to shed some additional light on the 
roles of HLCS in cell biology and signaling. 
 
Materials and Methods 
Prediction of HLCS-binding proteins 
In previous studies, we have shown that HLCS-binding proteins in chromatin share the 
GGGG(K/R)G(I/M)R motif (Li et al., 2013). A BLAST search was conducted to identify 
proteins containing this motif, revealing N-CoR as a candidate for binding to HLCS (see 
Results). N-CoR ushers histone deacetylases HDAC1and 2 to N-CoR docking sites, 
thereby facilitating histone deacetylation and a repressive chromatin environment (Alland 
et al., 1997; Heinzel et al., 1997; Nagy et al., 1997). The amino acid sequences in 
HDAC1 and HDAC2 are 83% identical, and the sequences in the catalytic core domain 
and the C-terminal tail are nearly identical (Brunmeir et al., 2009). Subsequent 
experiments used HDAC1 as a model for deacetylases. 
Cell lines and HLCS overexpression 
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Human embryonic kidney HEK293 cells (American Type Culture Collection) were 
cultured in Dulbecco's Modified Eagle's Medium (Thermo Scientific) containing 10% 
fetal bovine serum, 1% L-glutamine, 1% penicillin/streptomycin and 0.1% sodium 
pyruvate. HLCS overexpression cells were created by transfecting HEK293 cells with 
plasmid FLAG/Myc-HLCS using electroporation as described previously (Xue et al., 
2013). The expression of HLCS was assessed by western blot analysis and quantitative 
real-time PCR (qRT-PCR) as described previously using the PCR primer pair denoted 
“25” in Table 1 (Chew et al., 2006). 
Plasmids 
Full-length human HLCS (GenBank NM_000411) was subcloned from plasmid 
pGBKT7-HLCS (Hassan et al., 2009a) into vectors pCMV-Myc and pCMV-HA 
(Clontech) using SfiI and SalI, thereby creating plasmids pCMV-Myc-HLCS and pCMV-
HA-HLCS. Previous studies suggest the existence of four distinct domains in human 
HLCS (Hassan et al., 2009a). Myc-tagged overexpression plasmids coding for the 
individual domains were created as described previously (Hassan et al., 2009a), using 
plasmid pGBKT7-HLCS as template, PCR primer pairs 1, 2, 3, and 4, and vector pCMV-
Myc as acceptor, thereby creating plasmids pCMV-Myc-HLCS-NT (N-terminus,S2-F446), 
pCMV-Myc-HLCS-CD (central domain,F471-S575), pCMV-Myc-HLCS-L (linker 
domain,T610-V668), and pCMV-Myc-HLCS-CT (C-terminus,H669-R718), respectively. 
Plasmid pET41a-HLCS codes for glutathione S-transferase (GST)-tagged recombinant 
HLCS and was prepared as described previously using PCR primer pair 5 (Bao et al., 
2011). 
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N-CoR (GenBank NM_006311) is a 270-kDa protein, containing three autonomous 
repression domains and a conserved bipartite nuclear receptor interaction domain 
(Horlein et al., 1995; Ishizuka and Lazar, 2005). In order to achieve reasonable 
transfection efficiencies (through keeping plasmids reasonably small) and to assign 
putative interactions with HLCS to distinct domains in N-CoR, the following three 
overlapping fragments of N-CoR were cloned using HEK293 cell cDNA as template 
(Fig. 2A): N-terminal domain (NT), central domain (CD), and C-terminal domain (CT). 
PCR reactions were conducted using primers 6 (NT), 7 (CD), and 8 (CT); PCR products 
were digested using EcoRI and KpnI and cloned into vectors pCMV-Myc and pCMV-
HA, thereby creating plasmids pCMV-Myc-N-CoR-NT, pCMV-Myc-N-CoR-CD, 
pCMV-Myc-N-CoR-CT, pCMV-HA-N-CoR-NT, pCMV-HA-N-CoR-CD, and pCMV-
HA-N-CoR-CT. Lysine (K) to arginine (R) mutations and GGGG(K/R)G(I/M)R motif 
deletion were created using pCMV-Myc-N-CoR-CT as template and the GENEART Site-
Directed Mutagenesis System (Invitrogen), thereby creating plasmids pCMV-Myc-N-
CoR-CTK2323R (primer pair 9), pCMV-Myc-N-CoR-CTK2325R (primer pair 10), and 
pCMV-Myc-N-CoR-CTdel (primer pair 11). For the preparation of recombinant proteins, 
pCMV-Myc-N-CoR-NT, pCMV-Myc-N-CoR-CD, and pCMV-Myc-N-CoR-CT were 
PCR amplified using primers 12, 13, and 14, and the three N-CoR domains were 
subcloned into the pET41a vector using EcoRI and SacI, thereby creating plasmids 
pET41a-N-CoR-NT, pET41a-N-CoR-CD, and pET41a-N-CoR-CT, respectively. 
HDAC1 (GenBank NM_004964) and its novel splicing variant HDAC1Δ31, which lacks 
the entire 31 amino acids encoded by exon 7 (Liu D and Zempleni J, unpublished), were 
cloned from HEK293 cell cDNA into vector pCMV-Myc and pCMV-HA using PCR 
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primer pair 15, and EcoRI and KpnI, thereby creating plasmids pCMV-Myc-HDAC1, 
pCMV-Myc-HDAC1Δ31, pCMV-HA-HDAC1, and pCMV-HA-HDAC1Δ31. HDAC 
reading frames were subcloned into the pET41a vector using PCR primer pair 16, and 
EcoRI and SacI to create plasmids pET41a-HDAC1 and pET41a-HDAC1Δ31 for 
preparing recombinant HDAC1 and HDAC1Δ31, respectively. 
Two fragments of Photinus pyralis firefly luciferase (N-terminus, E2-G416; C-terminus, 
M398-C550) were cloned and used to create split luciferase reporter plasmids. The N-
terminal fragment was cloned using plasmid pGL3-Control (Promega) as template 
(primer pair 17) and inserted into pCMV-Myc, pCMV-Myc-HLCS, and pCMV-Myc-
TP53 using KpnI and NotI, thereby creating plasmids pCMV-Myc-NLuc, pCMV-Myc-
HLCS-NLuc, and pCMV-Myc-TP53-NLuc. The C-terminal fragment was also cloned 
using plasmid pGL3-Controlas template (primer pair 18) and inserted into pCMV-Myc, 
pCMV-Myc-N-CoR-NT, pCMV-Myc-N-CoR-CD, pCMV-Myc-N-CoR-CT, pCMV-
Myc-HDAC1, pCMV-Myc-HDAC1Δ31, pCMV-Myc-MDM2, and pCMV-Myc-
CDK3using SfiI and EcoRI, thereby creating plasmids pCMV-Myc-CLuc, pCMV-Myc-
N-CoR-NT-CLuc, pCMV-Myc-N-CoR-CD-CLuc, pCMV-Myc-N-CoR-CT-CLuc, 
pCMV-Myc-HDAC1-CLuc, pCMV-Myc-HDAC1Δ31-CLuc, pCMV-Myc-MDM2-CLuc, 
and pCMV-Myc-CDK3-CLuc, respectively (Fig. 2B). 
The following control plasmids were created for the split luciferase complementation 
assay. Human tumor suppressor TP53 (GenBank NM_000546) was cloned from HEK293 
cell cDNA into vector pCMV-Myc using primer pair 19 and SfiI and SalI, thereby 
creating plasmid pCMV-Myc-TP53. E3 ubiquitin-protein ligase MDM2 (GenBank 
NM_002392) and cyclin-dependent kinase 3 (CDK3; Genbank NM_001258) were cloned 
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from HEK293 cell cDNA into vector pCMV-Myc using ECoRI and XhoI, thereby 
creating plasmid pCMV-Myc-MDM2 (primer pair 20) and pCMV-Myc-CDK3 (primer 
pair 21). 
Co-immunoprecipitation assays 
HEK293 cells were co-transfected with equal amounts of overexpression and control 
vectors in permutations as described in Results, using TurboFect reagent (Thermo 
Scientific) according to the manufacturer’s instructions (Fermentas). Cells (4 x 106) were 
collected 24 h after transfection and lysed in 20 mM Tris HCl buffer (pH 8.0), containing 
137 mM NaCl, 10% glycerol, 1% Triton X-100, and 2 mM EDTA, phenylmethylsulfonyl 
fluoride, and protease inhibitor cocktail (Sigma-Aldrich). Target proteins were 
precipitated with mouse monoclonal anti-Myc (Origene), rabbit polyclonal anti-HA 
(Abcam), and 100 µL settled protein A beads (Pierce). Precipitated proteins were boiled 
in LDS (lithium dodecyl sulfate) sample buffer (Invitrogen) and analyzed by western blot 
with the antibodies named in Results. Non-transfected HEK293 cells were used as 
negative controls.  
Limited proteolysis assays 
This assay is based on the principle that the proteolytic digestion of proteins by dilute 
proteases is slowed, if two or more proteins interact physically (Chazin, 2007). 
Recombinant proteins were overexpressed in Arctic Express (DE3) competent cells 
(Stratagene) and purified using GSTrap HP Columns (GE Healthcare) according to the 
manufacturer's instructions. The GST tag was removed using thrombin, and the identity 
of recombinant proteins was assessed by western blot analysis. Limited proteolysis assays 
were performed using recombinant HLCS and equal amounts of recombinant N-CoR 
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fragments, HDAC1, or HDAC1Δ31 in 150 mM Tris acetate buffer (pH 7.5), containing 
0.6 mM dithiothreitol and 90 mM MgCl2. After 1 h of pre-incubation at 37°C, aliquots 
were collected prior to  addition of trypsin (10 ng trypsin/µg recombinant protein; Sigma-
Aldrich), and equal volumes of aliquots were collected at timed intervals after initiation 
of digestion. Digestion of proteins was visualized by gel electrophoresis and staining with 
coomassie blue. 
Split luciferase complementation assay 
This assay is based on the principle that luciferase produces chemiluminescence only if 
its N- and C-termini are in close physical proximity (Luker and Piwnica-Worms, 2004). 
If the N- and C-terminal fragments of luciferase are fused to proteins, chemiluminescence 
will be produced only if the two fusion proteins interact physically, thereby bringing the 
luciferase termini in close physical proximity. HEK293 cells were co-transfected with 
equal amounts of luciferase fusion constructs using TurboFect reagent. Cells were 
collected 48 h after transfection and cell suspension was mixed with an equal volume of 
LucLite substrate (Promega). Luminescence was quantified using a microplate 
scintillation and luminescence counter (Packard) and normalized by β-gal activity as 
described previously (Griffin et al., 2003). Fusion constructs of TP53and MDM2 were 
used as positive controls (ElSawy et al., 2013); fusion construct of TP53and CDK3 were 
used as negative controls (Tsuji et al., 2002). 
Biotinylation of HLCS-binding proteins by recombinant HLCS 
There is precedent for the HLCS-dependent covalent binding of biotin to chromatin 
proteins such as EHMT-1 and histones (Bao et al., 2011; Li et al., 2013). We determined 
whether putative HLCS-interacting proteins are potential targets for biotinylation by 
41 
 
 
 
HLCS. Briefly, recombinant N-CoR fragments, HDAC1, and HDAC1Δ31were incubated 
with recombinant HLCS in biotinylation buffer and protein-bound biotin was probed with 
anti-biotin (Abcam) as described previously (Hassan et al., 2009b). Equal loading of gels 
was confirmed using coomassie blue. 
Micro chromatin immunoprecipitation (μChIP) assay 
The enrichment of histone H3 K9-acetylation (H3K9ac) marks in long terminal repeats 
(LTRs) 15 and 22 and pericentromeric alpha satellite repeats in chromosomes 1 
(Chr1alpha) and 4 (Chr4alpha) in HLCS overexpressed cells was assessed by μChIP as 
described (Dahl and Collas, 2008; Pestinger et al., 2011). ChIP grade anti-H3K9ac and 
anti-H3 (Abcam) were used to precipitate chromatin associated with H3K9ac marks and 
to normalize for nucleosomal occupancy, respectively. The promoter regulating the 
expression of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) localizes in 
euchromatin and was used as control locus. Data are expressed as percentage of input 
DNA. 
qRT-PCR 
The abundance of mRNA coding for LTRs 15 and 22 and Chr1alpha and Chr4alpha was 
quantified by qRT-PCR using Power SYBR Green PCR Master Mix (Applied 
Biosystems). PerfeCTa SYBR Green FastMix (Quanta Biosciences) was used to quantify 
the abundance of amplicons in immunoprecipitated chromatin (Pestinger et al., 2011). 
PCR primer pairs are listed in Supplementary Online Table S1 (Buzdin et al., 2006; 
Kovalskaya et al., 2006). 
Statistics 
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Data were tested for normality of distribution by Komolgorov-Smirnov normality test. 
Data from split luciferase complementation assays were tested for homogeneity of 
variances by Bartlett's test and analyzed for significance of difference by one-way 
ANOVA. Data from μChIP and qRT-PCR were tested for homogeneity of variances by 
F-test and analyzed by student’s t-test (SAS, 2008). Variances of data from qRT-PCR 
testing HLCS expression levels were heterogeneous and therefore the conservative 
Mann-Whitney U test was used for analysis. All analyses and data points are based on 
three biologically independent repeats. StatView 5.0.1 (SAS Institute) was used to 
perform all calculations. Differences were considered significant if p<0.05. Data are 
expressed as means ± S.D. 
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Table 1.1 PCR primers. 
P1 Target;
2 
template Primer Sequences 5’→ 3’ F/R 
1 
HLCS-NT 
cDNA 
GCCGAATTCCCATGGAAGATAGACTCC F 
CAGGTCGACCCGAAGGCCTCCATGTTG R 
2 
HLCS-CD 
cDNA 
GCCGAATTCCCTTTGCCGAAGTGACCC F 
CAGGTCGACCCGTCACTGTAATAAATA R 
3 
HLCS-L 
cDNA 
GCCGAATTCCCACCATCTGCATCAACG F 
CAGGTCGACCCGTGGACCCAGTATCGG R 
4 
HLCS-CT 
cDNA 
GCCGAATTCACAGTGGTCAGCAAGTCC F 
CAGGTCGACTCTCAGCATGTCGAAGGA R 
5 
HLCS 
cDNA 
GTCCGAATTCGGGGAGCATGTTGGCAGAG F 
ATTTCTCGAGCCCGCCGTTTGGGGAG R 
6 
N-CoR-NT 
cDNA 
GCGGAATTCCCTCAAGTTCAGGTTATCCT F 
GCGGGTACCATCCAAGTCTCTTTCTTTGG R 
7 
N-CoR-CD 
cDNA 
GCGGAATTCCCACCAAAGCTGACTCTGT F 
GCGGGTACCAGCACTTGCAGCAGCTGC R 
8 
N-CoR-CT 
cDNA 
GCGGAATTCCCCCTGGTACACAGATTACTTT F 
GCGGGTACCGTCATCACTATCCGACAGG R 
9 
CTK2323R 
cDNA 
TCAGGAGGAGTTTGCAGACCAAAGCTGATCAGC F 
TTTGGTCTGCAAACTCCTCCTGAATGAGGTGAT R 
10 
CTK2325R 
cDNA 
GGAGTTTGCAAACCAAGGCTGATCAGCAAGTCA F 
ATCAGCCTTGGTTTGCAAACTCCTCCTGAATGA R 
11 
CTdel 
cDNA 
CCATCACCTCATTCAAGCAAGTCAAACAGC F 
TGCTTGAATGAGGTGATGGGTCCCCTTCCT R 
12 
N-CoR-NT 
cDNA 
GCGGAATTCTCAAGTTCAGGTTATCCTCC F 
GCGGAGCTCATCCAAGTCTCTTTCTTTGG R 
13 
N-CoR-CD 
cDNA 
GCGGAATTCACCAAAGCTGACTCTGTGG F 
GCGGAGCTCAGCACTTGCAGCAGCTGC      R 
14 
N-CoR-CT 
cDNA 
GCGGAATTCCCTGGTACACAGATTACTTTCC F 
GCGGAGCTCGTCATCACTATCCGACAGG      R 
15 HDAC1/Δ31 GCGGAATTCAAGCGCAGACGCAGGG F 
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cDNA GCGGGTACCGGCCAACTTGACCTCCTCCTTG R 
16 
HDAC1/Δ31 
cDNA 
GCGGAATTCAAGCGCAGACGCAGGG  F 
GCGGAGCTCGGCCAACTTGACCTCCTCCTTG R 
17 
NLuc 
cDNA 
CCCGTCGACCGAAGACGCCAAAAAC F 
CCCGCGGCCGCTCCATCCTTGTCAAT R 
18 
CLuc 
cDNA 
GCGGGCCATGGAGGCCATGTCCGGT F 
GCGGAATTCGCACGGCGATCTTTCCG R 
19 
TP53 
cDNA 
CGGCCATGGAGGCCGAGGAGCCGCAGTCA F 
GCGGTCGACCGTCTGAGTCAGGCCCTTCTGTC R 
20 
MDM2 
cDNA 
GCGGAATTCCCGTGAGGAGCAG F 
GCGCTCGAGAGGGGAAATAAGTTAGCA R 
21 
CDK3 
cDNA 
GCGGAATTCCCGATATGTTCCAGAA F 
GCGCTCGAGAATGGCGGAATCGCT R 
22 
LTR15 
gDNA 
TTGTCATTGGTTCTGTGTAGGG F 
CCTCCATATGCTGAACGCTG R 
23 
LTR22 
gDNA 
ATGGATTCAGCCTGTGTCTTTGGG F 
CCTCCATATGCTGAACGCTG R 
24 
GAPDH 
gDNA 
ATGACAAGCATGAGGCAGAG F 
CAACCAGGACCGTTAACCCTTTCT R 
25 
HLCS 
cDNA 
ATGGAAGATAGACTCCACAT F 
TGAGACCTGATCCTTAACTTCC R 
26 
U5 
cDNA 
AACTCAGAGGCTGGCG F 
AGACACAGAGACAAAGTATAGAGA R 
27 
R-U5 
cDNA 
GCGGGCAGCAATACTGCTTTGTAA F 
ACCAGCGTTCAGCATATGGAGGAT R 
28 
GAPDH 
cDNA 
TCCACTGGCGTCTTCACC F 
GGCAGAGATGATGACCCTTT R 
29 
Chr1alpha 
cDNA, gDNA 
CATCGAATGGAAATGAAAGGAGTC F 
ACCATTGGATGATTGCAGTCAA R 
30 
Chr4alpha 
cDNA, gDNA 
CTGCACTACCTGAAGAGGAC F 
GATGGTTCAACACTCTTACA R 
1Abbreviations: cDNA, complementary DNA; F, forward; gDNA, genomic DNA; 
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P, primer pair; R, reverse; R-U5 = region between R and U5 of LTR of HERV-K 
families; U5 = U5 region of LTR of HERV-K families.  
2Genbank entries: Chr1alpha = chromosome 1 alpha satellite repeats (M26919); 
Chr4alpha = chromosome 4 alpha satellite repeats (M38467); CDK3 = cyclin-dependent 
kinase 3 (NM_001261); GAPDH = glyceraldehyde-3-phosphate dehydrogenase 
(NG_007073 for genomic DNA, NM_002046 for complementary DNA); HDAC1 = 
histone deacetylase 1 (NM_004964); HLCS = holocarboxylase Synthetase 
(NM_000411); LTR15 = intact LTR (AC116309); LTR22 = solitary LTR (AL451165); 
MDM2 = E3 ubiquitin-protein ligase MDM2 (NM_002392); N-CoR = nuclear receptor 
corepressor (NM_006311); TP53 = tumor protein p53 (NM_000546). 
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Figures and legends 
 
Figure 1.1 HLCS-containing multi-protein gene repression complex. The binding of 
HLCS to chromatin depends on physical interactions of HLCS with the maintenance 
DNA methyltransferase DNMT1 and the methyl CpG binding protein 2, MeCP2. 
Chromatin-bound HLCS recruits the eukaryotic histone H3 methyltransferase EHMT-1, 
nuclear receptor corepressor N-CoR, and histone deacetylases HDACs. 
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Figure 1.2 Schematics of domains in N-CoR and luciferase constructs used in the split 
luciferase complementation assays. (A) The N-terminus of N-CoR contains 
transcriptional repression domains (RDs) responsible for the recruitment of additional 
components of the corepressor complex such as HDACs, mSin3, and GPS2. A pair of 
potent repressor motifs known as SANT motifs (SWI3, ADA2, N-CoR, and TFIIIB) is 
positioned between the RDs; SANT motifs recruit HDAC3 and histones to the repressor 
complex in order to enhance HDAC3 activity. The C-terminus of N-CoR includes a 
nuclear receptor interaction domain (NID), which binds ligand-free nuclear receptors. In 
order to assign putative interactions with HLCS to distinct domains in N-CoR, three 
overlapping fragments of N-CoR were cloned, N-terminal domain (NT), central domain 
(CD), and C-terminal domain (CT). (B) In split luciferase complementation assays, N-
terminal and C-terminal fragments are fused to interacting proteins. Physical interactions 
between the two proteins reconstitute luciferase activity. 
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Figure 1.4 Split luciferase complementation assays for detection of HLCS and N-CoR 
interaction in HEK293 cells. Fusion constructs of TP53 and MDM2 were used as positive 
controls, and TP53 and CDK3 were used as negative controls. Values are the mean ± S.D. 
of independent experiments (n=3; *p-value<.01 vs. background control for self-
association and negative control). 
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Figure 1.6 Split luciferase complementation assays for detection of HLCS and HDAC1s 
interaction in HEK293 cells. Fusion constructs of TP53 and MDM2 were used as positive 
controls, and TP53 and CDK3 were used as negative controls. Values are the mean ± S.D. 
of independent experiments (n=3; *p-value<.01 vs. background control for self-
association and negative control). 
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Abstract 
Lysine specific demethylase 1 (LSD1) is a flavin adenine dinucleotide (FAD)-dependent 
demethylase that catalyzes the removal of methyl groups from lysine-4 in histone H3 
(H3K4me1, H3K4me2), thereby mediating gene repression. Here we tested the 
hypothesis that riboflavin deficiency causes a loss of LSD1 activity in human 
hepatocarcinoma HepG2 cells, leading to an accumulation of H3K4me2 marks in the 
albumin promoter and aberrant up-regulation of albumin expression. Cells were cultured 
in riboflavin-defined media providing riboflavin at levels representing moderately 
deficient (3.1 nmol/L), sufficient (12.6 nmol/L), and supplemented (301 nmol/L) in 
humans for 7 days. Efficacy of treatment was confirmed by assessing glutathione 
reductase activity and levels of reduced glutathione as markers of riboflavin status. LSD 
activity was 21% greater in riboflavin-supplemented cells compared with riboflavin-
deficient and sufficient cells. Loss of LSD activity was associated with a gain in the 
abundance of H3K4me2 marks in the albumin promoter; the abundance of H3K4me2 
marks was about 170% higher in riboflavin-deficient cells compared with sufficient and 
supplemented cells. The abundance of the repression mark, K9-trimethylated histone H3 
(H3K9me3) was 38% lower in the albumin promoter of riboflavin-deficient cells 
compared with the other treatment groups. The expression of albumin mRNA was 
aberrantly increased by 200% in riboflavin-deficient cells compared with sufficient and 
supplemented cells. In conclusion, riboflavin deficiency impairs gene regulation by 
epigenetic mechanisms, mediated by a loss of LSD1 activity. 
 
Key Words: albumin, LSD1, H3K4me2, demethylation, riboflavin  
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Introduction 
Riboflavin is an essential precursor in the synthesis of the flavocoenzymes, FMN, and 
FAD (Pinto and Rivlin, 2013). FMN and FAD, and their reduced forms FMNH2 and 
FADH2, serve as coenzymes in a large number of redox reactions and also a 
comparatively small number of reactions with no net redox change in mammalian 
intermediary metabolism (Bornemann, 2002; Henriques et al., 2010; Pinto and Rivlin, 
2013). Representative examples of flavin-dependent pathways include reactions in 
electron transport chain, citric cycle, fatty acid β-oxidation, glutathione homeostasis, and 
protein folding. In most cases, flavocoenzymes are not covalently attached to apoproteins 
but form noncovalent complexes (Janin and Chothia, 1978). Flavin metabolites other than 
riboflavin, FMN, and FAD have been identified in human plasma and urine by 
McCormick and co-workers (Chastain and McCormick, 1987a; Chastain and 
McCormick, 1987b; Chastain and McCormick, 1988; Zempleni et al., 1996a), but these 
metabolites probably lack biological activity. 
Rather recently, a new FAD-dependent enzyme has been identified: the nuclear amine 
oxidase homolog, lysine specific demethylase 1 (LSD1) (Shi et al., 2004; Culhane and 
Cole, 2007). LSD1 demethylates lysine-4 in monomethylated (H3K4me1) and 
dimethylated (H3K4me2) histone H3, thereby removing gene activation marks and 
mediating gene repression (Forneris et al., 2005; Kouzarides and Berger, 2007). 
H3K4me1 and H3K4me2 are enriched in chromatin adjacent to transcription start sites of 
active genes, whereas inactive gene promoters are characterized by low levels of H3K4 
methylation marks (Barski et al., 2007). Consistent with its role as a transcriptional 
repressor, LSD1 forms a complex with the REST corepressor and histone deacetylases 1 
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and 2, which synergize with LSD1 in gene repression by mediating the deacetylation of 
histone tails (Humphrey et al., 2001; You et al., 2001; Hakimi et al., 2002). 
Loss of LSD1 precipitates strong phenotypes. For example, LSD1 knockout is embryonic 
lethal in mice (Wang et al., 2007). LSD1-deficient mouse embryonic stem cells are 
characterized by defects in differentiation, severe growth impairments due to increased 
cell death and impaired cell cycle progression, and global DNA hypomethylation (Wang 
et al., 2009). 
To date, there is no published report regarding the impact of riboflavin nutrition on LSD1 
activity. This knowledge gap has possible implications for disease prevention, because a 
variety of factors can cause riboflavin depletion, including alcohol consumption (Pinto et 
al., 1987; Horvath, 2012), genetic defects of riboflavin transporter genes (Pinto et al., 
1987; Horvath, 2012), impaired conversion of riboflavin to its coenzyme forms in 
persons with thyroid hormone insufficiency (Cimino et al., 1987), and abnormal 
riboflavin metabolism such as inhibition of the incorporation of riboflavin into FAD in 
response to treatment with tricyclic and tetracyclic compounds such as chlorpromazine, 
tetracycline, and adriamycin (Pinto et al., 1981; Dutta et al., 1988). Note that current 
recommendations for riboflavin intake are largely based on studies using the FAD-
dependent glutathione reductase as marker of riboflavin nutrition, without considering the 
potentially more subtle FAD-dependent changes in the epigenome (Beutler, 1969a; 
Beutler, 1969b; National, 1998). 
Human hepatocarcinoma HepG2 cells were chosen as model in this study because flavin-
dependent pathways in these cells respond robustly to changes in riboflavin 
concentrations in culture media, when testing levels that represent moderate deficiency, 
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sufficiency, and supplementation in adults (Manthey et al., 2005; Werner et al., 2005; 
Manthey et al., 2006). The albumin gene was chosen as a target locus because HepG2 
cells produce albumin in large quantities and albumin plays crucial roles in serum 
osmolarity and transport of vitamins, fatty acids, and hormones (Bernardi et al., 2012). 
Using this model system, we tested the hypothesis that riboflavin deficiency causes a loss 
of LSD1 activity, leading to an enrichment of H3K4me2 marks in the albumin gene locus 
and an aberrantly high expression of albumin gene. 
 
Results 
Treatment efficacy 
HepG2 cells showed the expected response to alterations in riboflavin concentrations in 
culture media, i.e., glutathione reductase activity was higher in riboflavin-supplemented 
cells compared with deficient and sufficient cells, and the levels of reduced glutathione 
were lower in riboflavin-deficient cells compared with sufficient and supplemented cells 
(Fig. 1A and B). These findings are consistent with efficacy of riboflavin treatment in 
HepG2 cell cultures in previous studies (Manthey et al., 2005; Manthey et al., 2006). 
LSD activity and expression 
LSD activity depended on the concentration of riboflavin in cell culture media. When 
HepG2 cells were cultured in riboflavin-defined medium for 7 days, LSD activity was 21% 
greater in riboflavin-supplemented cells compared with deficient and sufficient cells (Fig. 
1C).  
The expression of LSD1 mRNA was about 30% higher in riboflavin-deficient cells than 
sufficient and supplemented cells (Fig. 1D). LSD1 protein abundance followed a similar 
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pattern (arbitrary units of gel densitometry): 9.44 ± 0.87 for deficient cells vs. 6.81 ± 0.87 
for sufficient cells vs. 3.93 ± 0.94 for supplemented cells (p<0.05 for all possible 
comparisons). 
Transcriptional regulation of the albumin gene 
Riboflavin deficiency caused an aberrant expression of albumin in HepG2 cells. The 
binding of LSD1 to the albumin promoter was about 90% greater in riboflavin-deficient 
cells compared with sufficient and supplemented cells after 7 days of culture (Fig. 1E). 
Despite the increase in LSD1 binding, the abundance of H3K4me2 and H3K9me3 marks 
was 170% higher and 38% lower, respectively, in the albumin promoter in riboflavin-
deficient cells compared with sufficient and supplemented cells (Fig. 1F and G). (See 
Discussion for a role of LSD1 in the regulation of H3K9me3 repression marks.) These 
changes in epigenetic activation and repression marks were associated with albumin 
mRNA levels 200% higher in riboflavin-deficient cells compared with sufficient and 
supplemented cells (Fig. 1H). 
 
Discussion 
While it was recognized nine years ago that LSD1 is a FAD-dependent enzyme (Shi et 
al., 2004), this is to our best knowledge the first study to demonstrate the importance of 
riboflavin nutrition in the regulation of the H3K4me-dependent gene expression. Our 
studies provide unambiguous evidence that LSD1 expression and chromatin binding is 
higher in riboflavin-deficient liver cells compared with sufficient and supplemented cells. 
This up-regulation was not sufficient to compensate for the depletion of the 
flavocoenzyme FAD and holo-LSD1 in riboflavin-deficient cells. Our studies suggest 
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that loss of LSD1 activity causes aberrant gene regulation in riboflavin-deficient cells, as 
assessed by the accumulation of H3K4me2 gene activation marks in the albumin 
promoter and increased albumin gene expression in riboflavin-deficient cells. 
We also discovered that the loss of catalytically active LSD1 was associated with a 38% 
decrease of H3K9me3 repression marks in the albumin promoter. This observation can be 
ascribed to the observed up-regulation of LSD1 expression and promoter binding in 
riboflavin-deficient cells, along the following lines of reasoning. Unambiguous evidence 
suggests that LSD1 recruits Jumonji C domain-containing protein JMJD2C to gene 
promoters; JMJD2C has trimethyl lysine demethylase activity, does not depend on FAD 
as coenzyme, and may catalyze the demethylation of H3K9me3 (Wissmann et al., 2007). 
We propose that high levels of apo-LSD1 to the albumin promoter causes local 
accumulation of JMJD2C, which then leads to the erasure of H3K9me3 marks. 
Collectively, the gain of the gene activation mark H3K4me2 and the loss of the gene 
repression mark H3K9me3 synergize in the transcriptional activation of the albumin gene 
in riboflavin-deficient cells. 
Note that albumin gene was chosen as a model, because it is expressed in large quantities 
by liver cells, is responsible for about 75% of plasma osmolarity, and hyperalbuminemia 
may lead to congestive heart failure and hypertension (Quinlan et al., 2005). Moreover, 
previous DNA microarray studies are consistent with aberrant gene regulation in 
riboflavin-deficient HepG2 cells (Manthey et al., 2006). 
The effects of riboflavin described in this study represent levels of riboflavin in the 
plasma of normal adults, spanning the range of moderately deficient pregnant women to 
users of over-the-counter riboflavin supplements (Zempleni et al., 1995; Zempleni et al., 
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1996b). It was not necessary to utilize physiologically irrelevant treatments such as zero 
riboflavin to elicit meaningful effects on LSD activity and gene regulation. We 
acknowledge the possibility that cells other than liver cells might be less susceptible to 
loss of flavin-dependent enzyme activities compared with liver cells. For example, 
previous studies suggest that HepG2 cells are more susceptible than human lymphoid 
Jurkat cells, when using FAD-dependent protein folding as marker (Sauberlich et al., 
1972; Manthey et al., 2005).  
We propose that this study depicts the effects of riboflavin depletion on gene regulation 
by LSD1, rather than LSD2, based on the following rationale. Although both LSD1 and 
LSD2 may catalyze demethylation of H3K4me1/2 through an FAD-dependent reaction 
(Karytinos et al., 2009), previous studies suggest that LSD2 may repress genes through a 
mechanism independent of its demethylase activity (Yang et al., 2010), suggesting partial 
functionality of LSD2 in states of riboflavin deficiency. LSD2 binds to coding regions, as 
opposed to promoters, where it synergizes with euchromatic histone methyltransferases 
EHMT1/2 and NSD3 in the regulation of transcriptional elongation (Fang et al., 2010).  
A few uncertainties remain and warrant further investigation. First, we did not formally 
assess whether apo- and holo-LSD1 bind to the albumin promoter with similar affinity. 
Such studies will be feasible only when antibodies become available that distinguish 
between apo- and the holo-LSD1. Second, histone demethylases other than LSD1 do not 
depend on FAD as coenzyme and might rescue FAD-deficient cells regarding H3K4me2 
demethylation events. Examples include the H3K4me2 demethylases JARID1A, 
JARID1B, JARID1C, and JARID1D, which belong to Jumonji AT-rich interactive 
domain subfamily of Jumonji C domain containing proteins (Christensen et al., 2007; 
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Iwase et al., 2007; Klose et al., 2007; Lee et al., 2007; Tahiliani et al., 2007; Yamane et 
al., 2007).  
Even though uncertainties remain, this study provides unambiguous evidence for a role of 
riboflavin nutrition in gene regulation by epigenetic mechanisms. Future studies will need 
to assess the extent by which moderate riboflavin deficiency causes aberrant gene 
regulation and disease in humans. 
 
Materials and Methods 
Cell cultures 
HepG2 human hepatocarcinoma cells (ATCC, Manassas, VA, passage number 5) were 
cultured in riboflavin-defined RPMI-1640 medium (HyClone, Logan, UT) as described 
previously (Camporeale and Zempleni, 2003; Manthey et al., 2006). Riboflavin 
concentrations in the culture medium were adjusted to 3.1 nmol/L (denoted deficient, 
“DEF”), 12.6 nmol/L (denoted sufficient, “SUF”), and 301 nmol/L (denoted 
supplemented, “SUP”), taking into account the residual concentrations of riboflavin, 
FMN, and FAD in dialyzed fetal bovine serum. Cells were cultured in riboflavin-
sufficient medium for 7 days before transfer into the riboflavin-defined medium and 
continued culture for 7 days before analysis. This protocol was chosen based on previous 
studies suggesting that HepG2 cells achieve new steady state levels of flavins within four 
days of culture in riboflavin-defined media and that cell proliferation was adversely 
impacted after 10 days of culture in riboflavin-deficient media (Manthey et al., 2005; 
Werner et al., 2005). Cells cultured in riboflavin-sufficient medium were designated as 
the control group. 
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Glutathione metabolism 
Glutathione reductase is an FAD-dependent enzyme and both the activity of glutathione 
reductase and the level of reduced glutathione are robust markers of riboflavin status 
(Camporeale and Zempleni, 2003; Manthey et al., 2006). After 7 days in riboflavin-
defined media, HepG2 cells were harvested and lysed for assessment of glutathione 
metabolism. Glutathione reductase activity was quantified in cell lysates containing 0.5 
mg protein as described previously (Sauberlich et al., 1972). One unit of glutathione 
reductase activity is defined as the change of absorbance at 340 nm per 0.5 mg protein in 
10 min of incubation. The concentration of reduced glutathione in lysates was determined 
colorimetrically using the 5,5-dithiobis(2-nitrobenzoic acid) reduction assay at 412 nm as 
described previously (Tietze, 1969).  
LSD activity 
LSD activity was measured using the demethylase (LSD-type) activity assay kit (Cayman 
Chemical, Ann Arbor, MI) according to the manufacturer’s instructions. One unit of LSD 
activity is defined as the ratio of sample fluorescence to background fluorescence. This 
assay does not distinguish between the two LSD in the human proteome, LSD1 and 
LSD2 (Fang et al., 2010).  
Western blot analysis 
LSD1 expression was quantified by western blot as described previously (Manthey et al., 
2006), using rabbit polyclonal anti-human LSD1 (Abcam, Cambridge, MA). GAPDH 
was probed using anti-GAPDH (Santa Cruz Biotechnology, Santa Cruz, CA) and used as 
loading control. Data were quantified by gel densitometry analysis. 
Chromatin immunoprecipitation (ChIP) assay 
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The enrichment of LSD1, H3K4me2, and  K9-trimethylated histone H3 (H3K9me3) in 
the promoter region of the human albumin gene (-166 to +58) was assessed by ChIP 
assay as described previously (Dahl and Collas, 2008). Immunoprecipitations were 
performed with specific antibodies to LSD1, H3K4me2 (Abcam), H3K9me3 (Abcam), 
H3 (Abcam), and rabbit IgG (Santa Cruz Biotechnology). Nuclear chromatin extracts 
without immunoprecipitation were used as input control. Precipitation of chromatin with 
non-specific rabbit IgG was used as negative control. Histone H3 occupancy was used to 
normalize H3K4me2 and H3K9me3 occupancy in the albumin promoter.  
qRT-PCR 
The abundance of mRNA coding for LSD1 and albumin was quantified by qRT-PCR 
using Power SYBR Green PCR Master Mix (Applied Biosystems, Carlsbad, CA) as 
described previously (Gralla et al., 2008) (Table 1). The relative amount of each gene 
was normalized using housekeeping gene GAPDH. 
Amplicons from ChIP assays were analyzed using the PerfeCTa SYBR Green FastMix 
(Quanta Biosciences, Gaithersburg, MD) as described previously (Pestinger et al., 2011). 
The relative occupancy of histones in the albumin promoter were calculated as described 
(Wei et al., 2006) and values are reported as the percent of input DNA. 
Statistical analysis 
Data were distributed normally and variances were homogenous, as assessed by 
Komolgorov-Smirnov normality test and Bartlett's test, respectively. Statistical 
significance was assessed by one-way ANOVA and Fisher’s protected least significant 
difference posthoc test (Institute, 1998). All analyses and data points are based on three 
biologically independent repeats. StatView 5.0.1 (SAS Institute, Cary, NC) was used to 
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perform all calculations. Differences were considered significant if p-value < 0.05. Data 
are expressed as means ± S.D. 
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Table 1.1 Oligonucleotide primers used for qRT-PCR  
Gene1 Sequence F/R2 Template 
ALB 
5’-CTTGAATGTGCTGATGACAGG-3’ F 
cDNA 
5’-GCAAGTCAGCAGGCATCTCAT-3’ R 
ALB 
5’-TACATTGACAAGGTCTTGTGGAG-3’ F 
gDNA 
5’-TGGGGTTGACAGAAGAGAAAAGC-3’ R 
GAPDH 
5’-TCCACTGGCGTCTTCACC-3’ F 
cDNA 
5’-GGCAGAGATGATGACCCTTT-3’ R 
GAPDH 
5’-ATGACAAGCATGAGGCAGAG-3’ F 
gDNA 
5’-CAACCAGGACCGTTAACCCTTTCT-3’ R 
LSD1 
5’-ACCACAACAGACCCAGAAGG-3’ F 
cDNA 
5’-GGTGCTTCTAATTGTTGGAGAG-3’ R 
1Genbank entries: ALB = Homo sapiens albumin (NM_000477.5); GAPDH = Homo 
sapiens glyceraldehyde-3-phosphate dehydrogenase (NM_002046.4 for complementary 
DNA, NG_007073.2 for genomic DNA); LSD1 = Homo sapiens lysine (K)-specific 
demethylase 1 (NM_001009999.2). 
2Abbreviations: cDNA, complementary DNA (for gene expression analysis); F, forward; 
gDNA, genomic DNA (for ChIP assays); R, reverse. 
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Figures and legends 
 
Figure 1.1 Effects of riboflavin concentrations in culture media on LSD1-dependent gene 
regulation in HepG2 cells. (A) Glutathione reductase activity; (B) reduced glutathione; (C) 
LSD activity; (D) expression of LSD1 mRNA and protein (insert); (E, F, G) enrichment 
of LSD1, H3K4me2, and H3K9me3, respectively, in the albumin promoter; and (H) 
albumin mRNA abundance. Values are means ± SD, n=3. a,bMeans not sharing a 
common letter are significantly different for the same variable, p-value < 0.05. DEF, 
deficient; SUF, sufficient; SUP, supplemented. 
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Abstract 
Mono- and dimethylation of lysine (K)-4 in histone H3 (H3K4me1, H3K4me2) creates 
epigenetic gene activation marks that are enriched near the transcription start site (TSS) 
of genes. Lysine specific demethylase 1 (LSD1) is a flavin adenine dinucleotide (FAD)-
dependent demethylase that catalyzes the demethylation of H3K4me1 and H3K4me2, 
thereby mediating gene repression. This study tested the hypothesis that LSD1 activity 
depends on the concentrations of the FAD precursor, riboflavin, in cell culture media, and 
that riboflavin deficiency causes de-repression of pro-inflammatory cytokines. Human T 
lymphoma Jurkat cells were cultured in riboflavin-defined media, representing plasma 
levels of riboflavin in moderately deficient, sufficient, and supplemented humans. The 
expression of LSD1 mRNA and protein followed the pattern riboflavin-deficient > 
riboflavin-sufficient > riboflavin-supplemented cells. However, the increase in LSD1 
expression was insufficient to compensate for FAD depletion, and LSD activities were 
more than 30% higher in riboflavin-supplemented cells compared with the other 
treatment groups. The enrichment of H3K4me2 marks was 11-137% greater in 
riboflavin-deficient cells compared with sufficient cells in exon 1 of genes coding for the 
pro-inflammatory cytokines interleukin (IL)-1α, IL-1β, IL-6, and tumor necrosis factor-α 
(TNF-α). Consistent with the enrichment of gene activation marks, the expression of 
mRNA coding for pro-inflammatory cytokines was 62-487% higher in riboflavin-
deficient cells compared with sufficient cells. These findings support the hypothesis that 
riboflavin deficiency contributes toward a pro-inflammatory gene expression pattern 
through a loss of LSD1 activity. 
Key Words: demethylation, FAD, H3K4me2, pro-inflammatory cytokines, TSS 
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Introduction 
Epigenetic marks play key roles in the regulation of gene expression. Post-translational 
methylation of histones is one such epigenetic event that contributes to gene regulation 
(Greer and Shi, 2012). Remarkable progress has been made in characterizing the 
distribution of histone methylation marks and assessing the roles these marks in gene 
regulation on a genome-wide scale in yeast and several mammalian cell lines (Bernstein 
et al., 2002; Barski et al., 2007; Koch et al., 2007; Lee and Mahadevan, 2009; Nair et al., 
2012). These studies implicate methylation of lysine (K)-4 in histone H3 in gene 
activation, whereas methylation of K-9 in histone H3 is implicated in gene repression. 
Within actively transcribed genes, some methylation marks, e.g., K4-monomethylated 
histone H3 (H3K4me1), K4-dimethylated histone H3 (H3K4me2), and K4-trimethylated 
histone H3 (H3K4me3), are enriched near transcription start sites (TSS) in genes (values 
denote basepairs relative to the TSS): -900 and +1000 for H3K4me1, -500 and +700 for 
H3K4me2, and -300 and +100 for H3K4me3 (Barski et al., 2007; Heintzman et al., 2007). 
Histone methyltransferases and demethylases are enzymes that create, maintain, and 
erase histone methylation marks. Lysine-specific demethylase 1 (LSD1, also known as 
KDM1A, BHC110 and AOF2) is the first histone demethylase that was discovered; it 
represses transcription by removing methyl groups from H3K4me1/2 (Shi et al., 2004; 
Karytinos et al., 2009). LSD1 is unique among multiple demethylases in that it belongs to 
the flavin-containing amine oxidase family and utilizes flavin adenosine dinucleotide 
(FAD) as an essential cofactor for catalytic activities (Forneris et al., 2005). FAD, 
produced by adenylation of the vitamin riboflavin, serves as a coenzyme in a large 
number redox reactions and a small number of reactions with no net redox change in 
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mammalian metabolism (Bornemann, 2002; Henriques et al., 2010; Pinto and Rivlin, 
2013). LSD1 is enriched in gene promoter regions as part of multiprotein gene repression 
complex (Wang et al., 2009; Foster et al., 2010; Whyte et al., 2012). LSD2 (also known 
as KDM1B and AOF1), the only mammalian homolog of LSD1, is also a member of the 
flavin-containing amine oxidase family. Like LSD1, LSD2 may also catalyze 
demethylation through the removal of methyl groups from H3K4me1/2 in an FAD-
dependent reaction (Zhang et al., 2012). Unlike LSD1, LSD2 is enriched in gene regions 
other than those adjacent to the TSS and forms protein complexes that regulate gene 
expression independent of FAD (Fang et al., 2010; Yang et al., 2010).  
Previous studies suggest that stimulation of pro-inflammatory genes causes changes in 
histone methylation patterns in promoter regions, consistent with a role of histone 
demethylases in the regulation of pro-inflammatory cytokines (Saccani and Natoli, 2002; 
El Gazzar et al., 2007; Foster et al., 2007). LSD1 may synergize with histone deacetylase 
1 to repress pro-inflammatory cytokines in breast cells and hepatocytes (Janzer et al., 
2012). Studies in diabetic mouse models specifically implicate LSD1 in the regulation of 
pro-inflammatory gene expression in vascular smooth muscle cells (Reddy et al., 2008; 
Wierda et al., 2010). 
It is widely recognized that nutritional factor play a role in methylation events, albeit the 
majority of previous studies focused on methyl donors (Zempleni et al., 2012). Here we 
tested the hypothesis that LSD1 activity depends on the concentrations of the FAD 
precursor, riboflavin, in cell culture media, and that riboflavin deficiency causes de-
repression of pro-inflammatory cytokines in human T lymphoma Jurkat cells. In addition, 
we assessed the distribution of H3K4me2 marks in regions upstream and downstream of 
88 
 
 
 
the TSS in pro-inflammatory genes. Jurkat cells were chosen as model, because 
riboflavin homeostasis has been well characterized in this cell line (Camporeale and 
Zempleni, 2003) and the cells express the pro-inflammatory cytokines interleukin (IL)-1α, 
IL-1β, IL-6, and tumor necrosis factor-α (TNF-α) when stimulated with phorbol esters 
(Wano et al., 1987; Khalaf et al., 2010). 
 
Results 
Determination of flavin status 
Glutathione reductase activity was 23% higher in riboflavin-supplemented Jurkat cells 
compared with riboflavin-sufficient cells, and the levels of reduced glutathione were 20% 
lower in riboflavin-deficient cells compared with riboflavin-sufficient cells (Fig. 2A). 
These observations are consistent with the notion that concentrations of riboflavin in 
culture media affected the intracellular flavin status, suggesting that treatment was 
effective (Camporeale and Zempleni, 2003). 
Expression of LSD1  
The expression of LSD1 mRNA was about 57% greater in riboflavin-deficient cells and 
24% less in riboflavin-supplemented cells compared with riboflavin-sufficient cells (Fig. 
2B). The protein abundance of LSD1 followed a similar pattern (arbitrary units of gel 
densitometry): 8.72 ± 0.96 for riboflavin-deficient cells vs. 6.31 ± 0.42 for riboflavin-
sufficient cells vs. 2.98 ± 0.56 for riboflavin-supplemented cells (p-value < 0.05 for all 
possible comparisons; n=3).   
LSD demethylase activity 
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LSD demethylase activity depended on the concentration of riboflavin in culture media. 
LSD activity was 33% greater in riboflavin-supplemented cells compared with riboflavin-
sufficient cells after 7 days of culture (Fig. 2C). No significant difference was observed 
between riboflavin-deficient and sufficient cells. 
Enrichment of H3K4me2 activation marks 
The abundance of H3K4me2 marks was higher in exon 1 in riboflavin-deficient cells 
compared with the other treatment groups. For example, the abundance of H3K4me2 
marks was 137%, 49%, and 27% higher in exon 1 in the IL-1α, IL-1β, and IL-6 genes, 
respectively, in riboflavin-deficient cells compared with riboflavin-sufficient cells (Fig. 
3A-C). Effects were comparably moderate for exon 1 in the TNF-α gene: the enrichment 
of H3K4me2 marks in exon 1 of the TNF-α gene was 11% higher in riboflavin-deficient 
cells and 17% lower in riboflavin-supplemented cells compared with riboflavin-sufficient 
cells (Fig. 3D). In contrast, effects of riboflavin on the abundance of H3K4me2 in the 
promoter region, as opposed to exon 1, of the four genes were not biologically 
meaningful (Fig. 3A-D).  
Expression of pro-inflammatory cytokines 
The levels of mRNA coding for pro-inflammatory cytokines were 62-487% greater in 
riboflavin-deficient cells compared with riboflavin-sufficient cells (Fig. 4A-D). In 
addition, mRNA levels of IL-1α and TNF-α were 12% and 19% lower, respectively, in 
riboflavin-supplemented cells compared with riboflavin-sufficient cells (Fig. 4A and D). 
 
Discussion 
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This is the first report to implicate riboflavin deficiency in the aberrant up-regulation of 
pro-inflammatory cytokines through loss of LSD1 activity. Our observations suggest that 
loss of LSD1 demethylase activity specifically affects the abundance of H3K4me2 marks 
in exon 1 regions of pro-inflammatory genes whereas the abundance of these marks in 
promoter regions was largely unaffected by riboflavin. Although higher LSD1 expression 
was observed in riboflavin-deficient cells, this up-regulation was not sufficient to 
compensate for the depletion of the flavocoenzyme FAD and holo-LSD1, as judged by 
the accumulation of H3K4me2 activation marks and increased pro-inflammatory gene 
expression in riboflavin-deficient cells. 
This paper has important implications for human health. Inflammation plays roles in 
diseases that affect a large percentage of the population, e.g., arthritis and inflammatory 
bowel disease. For example, 22% of U.S. adults suffer from doctor-diagnosed arthritis, 
and 9% have arthritis-attributable activity limitations (Centers, 2010). Evidence suggests 
that pro-inflammatory cytokines IL-1β, IL-6, and TNF-α, produced by synovial cells and 
infiltrating cells, actively participate in synovitis and joint destruction and have been 
linked with rheumatoid arthritis (Arend and Dayer, 1995; Brennan and McInnes, 2008; 
Corvaisier et al., 2012).  
LSD1, rather than LSD2, mediates the effects of riboflavin deficiency on gene expression. 
Although peptide demethylation assays cannot distinguish between the two LSD 
homologs, previous studies demonstrate that LSD2 specifically associates with the 
coding region of its target genes where it synergizes with euchromatic histone 
methyltransferases EHMT1/2 and NSD3 in the regulation of transcriptional elongation 
(Fang et al., 2010). In addition, LSD2 may repress genes through its LSD2-specific Zf-
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CW domain (Yang et al., 2010), suggesting that LSD2 may be functional in states of 
riboflavin deficiency. 
A few uncertainties remain and need further investigation. First, we did not assess the 
actual binding of LSD1 around TSS, based on the rationale that such studies would need 
to be performed using ChIP assays and antibodies that distinguish between apo- and the 
holo-LSD1. No such antibodies are currently available. Second, the impaired H3K4me2 
demethylation in riboflavin-deficient cells might be rescued by FAD-independent histone 
demethylases, such as H3K4me2 demethylases JARID1A, JARID1B, JARID1C, and 
JARID1D, which belong to Jumonji AT-rich interactive domain subfamily of Jumonji C 
domain containing proteins (Christensen et al., 2007; Iwase et al., 2007; Klose et al., 
2007; Lee et al., 2007; Tahiliani et al., 2007; Yamane et al., 2007). 
Future work is required to determine the underlying mechanism of LSD1-mediated 
repression of pro-inflammatory cytokines by riboflavin and its implication in human 
health. A logical next step would be to assess effects of riboflavin deficiency in a mouse 
feeding study. 
 
Materials and Methods 
Cell cultures 
Human T lymphoma Jurkat cells (ATCC, Manassas, VA, USA) were cultured in 
riboflavin-defined RPMI-1640 medium (HyClone, Logan, UT, USA) as described 
previously (Camporeale and Zempleni, 2003; Manthey et al., 2006). Riboflavin 
concentrations in the culture media were adjusted to 3.1 nmol/L (denoted deficient, 
“DEF”), 12.6 nmol/L (denoted sufficient, “SUF”), and 301 nmol/L (denoted 
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supplemented, “SUP”), taking into account the residual concentrations of riboflavin, 
flavin mononucleotide (FMN), and FAD in dialyzed fetal bovine serum. Cells were 
cultured in riboflavin-sufficient medium for 7 days before transfer into the riboflavin-
defined and continued culture for 7 days before analysis. This protocol was chosen based 
on previous and preliminary studies suggesting abnormally slow cell growth after 10 days 
of culture in riboflavin-deficient media (Manthey et al., 2005; Werner et al., 2005). The 
production of pro-inflammatory cytokines was induced by treatment with 100 μg/L 
phorbol 12-myristate 13-acetate (PMA) for 8 h before analysis (Khalaf et al., 2010). Cells 
cultured in riboflavin-sufficient medium were designated as the control group. 
Glutathione metabolism 
The activity of glutathione reductase and the level of reduced glutathione were used as 
markers of FAD status in Jurkat cells (Camporeale and Zempleni, 2003; Manthey et al., 
2006). After 7 days of culture in riboflavin-defined media, Jurkat cells were harvested 
and lysed for assessment of glutathione metabolism. Glutathione reductase activity was 
quantified in cell lysates containing 0.5 mg protein as described previously (Sauberlich et 
al., 1972). One unit of glutathione reductase activity is presented by the change of 
absorbance at 340 nm per 0.5 mg protein in 10 min of incubation. The concentration of 
reduced glutathione in lysates was determined colorimetrically using the 5,5-dithiobis(2-
nitrobenzoic acid) reduction assay as described previously (Tietze, 1969). The assay was 
calibrated using chemically pure reduced glutathione.  
Western blot analysis 
Expression of LSD1 protein was quantified by western blot as described previously 
(Manthey et al., 2006), using rabbit polyclonal anti-human LSD1 (Abcam, Cambridge, 
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MA, USA). Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was probed using 
mouse monoclonal anti-human GAPDH (Santa Cruz Biotechnology, Santa Cruz, CA, 
USA) and used as loading control. Data were quantified by gel densitometry analysis. 
LSD demethylase activity 
The assessment of LSD demethylase activity was conducted in Jurkat cells after 7 days of 
culture in riboflavin-defined media with demethylase (LSD-type) activity assay kit 
(Cayman Chemical, Ann Arbor, MI, USA) according to the manufacturer’s instructions. 
One unit of LSD activity is defined as the ratio of sample fluorescence to background 
fluorescence. This assay does not distinguish between the two LSD in the human 
proteome, LSD1 and LSD2 (Culhane and Cole, 2007).  
Chromatin immunoprecipitation (ChIP) assay 
The enrichment of H3K4me2 marks near the TSS of human pro-inflammatory genes such 
as IL-1α, IL-1β, IL-6, and TNF-α was assessed by ChIP assay as described previously 
(Dahl and Collas, 2008). Immunoprecipitations were performed with specific antibodies 
to H3K4me2 (Abcam), H3 (Abcam), and rabbit IgG (Santa Cruz Biotechnology). Nuclear 
chromatin extracts without immunoprecipitation were used as input control. Precipitation 
of chromatin with non-specific rabbit IgG was used as negative control and produced 
signals less than 10% compared with those produced by target-specific antibodies. 
Precipitations with H3 antibody were used to normalize for H3K4me2 occupancy in pro-
inflammatory genes.  
Quantitative real-time PCR (qRT-PCR) 
The abundance of mRNA coding for LSD1 and pro-inflammatory cytokines was 
quantified by qRT-PCR using Power SYBR Green PCR Master Mix (Applied 
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Biosystems, Carlsbad, CA, USA) as described previously (Gralla et al., 2008). The 
relative amount of each gene was normalized using housekeeping gene GAPDH.  
Amplicons from ChIP assays were analyzed using the PerfeCTa SYBR Green FastMix 
(Quanta Biosciences, Gaithersburg, MD, USA) as described previously (Pestinger et al., 
2011). The relative occupancy of H3K4me2 in pro-inflammatory gene regulatory regions 
was calculated as described previously (Wei et al., 2006) and values are reported as the 
percent of input DNA. To investigate the enrichment of H3K4me2 marks surrounding the 
TSS of genes coding for pro-inflammatory cytokines, primers were designed to amplify 
sequences upstream (denoted “promoter”) or downstream (denoted “exon 1”) of the TSS 
(Fig. 1), using ChIP samples as template (Barski et al., 2007; Heintzman et al., 2007) 
(Table 1). 
Statistical analysis 
Data exhibited normal distributions and homogenous variances, as assessed by 
Komolgorov-Smirnov normality test and Bartlett's test, respectively. Statistical 
significance was assessed by one-way ANOVA and Fisher’s protected least significant 
difference posthoc test (Institute, 1998). StatView 5.0.1 (SAS Institute, Cary, NC) was 
used to perform all calculations. Differences were considered significant if p-value < 
0.05. Data are expressed as means ± S.D. 
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Table 3.1 Oligonucleotide primers used for qRT-PCR 
Gene1 Sequence (5’-3’) F/R2 Template 
GAPDH 
TCCACTGGCGTCTTCACC F 
cDNA 
GGCAGAGATGATGACCCTTT R 
GAPDH 
ATGACAAGCATGAGGCAGAG F 
gDNA 
CAACCAGGACCGTTAACCCTTTCT R 
IL-1α 
ACAAAAGGCGAAGAAGACTGA F 
cDNA 
GGAACTTTGGCCATCTTGAC R 
IL-1α (-319 to -56) 
CCAACTCACACAAGCTGCTTT F 
gDNA 
GGTGGTAGAACACCAGACTCTT R 
IL-1α (+128 to +416) 
CTTCTTCTACAGAAGACACACCTT F 
gDNA 
CTGAAGAGGGAAGTTTGCTTGATT R 
IL-1β 
CTGTCCTGCGTGTTGAAAGA F 
cDNA 
TTGGGTAATTTTTGGGATCTACA R 
IL-1β (-235 to -67) 
ATATTTGCATGGTGATACATTTGC F 
gDNA 
CTCTGTTGAATACCTGATTTCACAA R 
IL-1β (+127 to +338) 
GCCTCTTTGTGTGTATGCATATT F 
gDNA 
GAGAGCTGGAGCAGAGGCTT R 
IL-6 
TCCAGAACAGATTTGAGAGTAGTG F 
cDNA 
GCATTTGTGGTTGGGTCAGG R 
IL-6 (-279 to -93) 
CTTCGTGCATGACTTCAGCTTT F 
gDNA 
GATTGTGCAATGTGACGTCCTTT R 
IL-6 (+132 to +398) 
CACAAGTAAGTGCAGGAAATCCTT F 
gDNA 
CGGCTACATCTTTGGAATCTT R 
LSD1 
ACCACAACAGACCCAGAAGG F 
cDNA 
GGTGCTTCTAATTGTTGGAGAG R 
TNF-α 
GCTCTTCTGCCTGCTGCACTT F 
cDNA 
GATGGCACCACCAGCTGGTT R 
TNF-α (-399 to -192) 
CCTGCATCCTGTCTGGAAGTT F 
gDNA 
GGGACACACAAGCATCAAGGAT R 
TNF-α (+103 to +374) GCTGCCAGGCAGGTTCTCTT F gDNA 
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GGCCAGGCACTCACCTCTT R 
1Genbank entries: GAPDH = Homo sapiens glyceraldehyde-3-phosphate dehydrogenase 
(NM_002046.4 for complementary DNA, NG_007073.2 for genomic DNA); IL-1α = 
Homo sapiens interleukin-1 alpha (NM_000575.3 for complementary DNA, 
NG_008850.1 for genomic DNA); IL-1β = Homo sapiens interleukin-1 beta 
(NM_000576.2 for complementary DNA, NG_008851.1 for genomic DNA); IL-6 = 
Homo sapiens interleukin-6 (NM_ NM_000600.3 for complementary DNA, 
NG_011640.1 for genomic DNA); LSD1 = Homo sapiens lysine (K)-specific demethylase 
1 (NM_001009999.2); TNF-α = Homo sapiens tumor necrosis factor-alpha 
(NM_000594.3 for complementary DNA, NG_007462.1 for genomic DNA). 
2Abbreviations: cDNA, complementary DNA (for gene expression analysis); F, forward; 
gDNA, genomic DNA (for ChIP assays); R, reverse. 
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Figures and legends 
 
Figure 3.1 Schematic of the region adjacent to the TSS in pro-inflammatory genes. 
Primers for were designed to amplify sequences upstream (“promoter”) or downstream 
(“exon 1”) of the TSS, respectively, in ChIP assays. 
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Figure 3.2 Glutathione metabolism (A), LSD1 expression (B), and LSD demethylase 
activity (C) depend on the concentrations of riboflavin in Jurkat cell culture media. The 
insert depicts a representative immunoblot of LSD1 protein. Values are means ± SD, n=3. 
a,b,cMeans not sharing a common letter are significantly different for the same variable, p-
value < 0.05. DEF, deficient; SUF, sufficient; SUP, supplemented. 
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Figure 3.3 Enrichment of H3K4me2 marks in IL-1α (A), IL-1β (B), IL-6 (C), and TNF-α 
(D) gene promoter and exon 1. Values are means ± SD, n=5. a,bMeans not sharing a 
common letter are significantly different for the same variable, p-value < 0.01. DEF, 
deficient; SUF, sufficient; SUP, supplemented. 
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Figure 3.4 The expression of IL-1α (A), IL-1β (B), IL-6 (C), and TNF-α (D) mRNA 
depends on the concentrations of riboflavin in Jurkat cell culture media. Values are 
means ± SD, n=3. a,b,cMeans not sharing a common letter are significantly different for 
the same variable, p-value < 0.05. DEF, deficient; SUF, sufficient; SUP, supplemented. 
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OUTLOOK 
 
We have demonstrated that HLCS plays an important role in gene regulation through the 
formation of multi-protein repression complex in human chromatin. Although several 
possible members of this complex have been identified and well characterized in cell 
cultures, a conditional HLCS knockout (KO) mouse model will allow us to validate 
previous in vitro observations and perform animal studies that are currently not feasible. 
Non-conditional KO mice are likely not viable based on observations that there is no 
living HLCS null individual. We are in the process of creating a conditional HLCS KO 
mouse in which expression can be controlled both spatially and temporally. These mice 
will allow us to knock out HLCS gene in specific tissues at defined developmental stages 
and investigate the impacts of HLCS on gene regulation and genome stability under 
controlled conditions. 
We observed that LSD1 mediates gene repression through epigenetic mechanisms that 
depend on sufficient riboflavin supply. Riboflavin deficiency has been documented in 
industrialized and developing nations and across various demographic groups, e.g., 
pregnant women, infants, and the elderly (National, 1998; Powers, 2003). Diseases such 
as cancer, cardiac disease, and diabetes mellitus have been linked with riboflavin 
deficiency (Cole et al., 1976; Steier et al., 1976; van Rensburg, 1981; Foy and Kondi, 
1984; Liu et al., 1993). These disease models should be assessed in the light of aberrant 
LSD1 activity. In addition, future studies will need to assess effects of riboflavin 
deficiency on inflammatory processes, considering that we observed an aberrantly high 
expression of inflammatory cytokines in cell cultures. 
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APPENDIX 
--- Raw data for each chapter 
Table 1 (Chapter I) Split luciferase complementation assays for detection of HLCS and 
N-CoR or HDAC1s interaction in HEK293 cells. 
Fusion constructs 
Luciferase activity ratio (arbitrary units) 
1 2 3 
HLCS-NLuc+N-CoR-NT-CLuc 2.231 2.577 2.644 
HLCS-NLuc+N-CoR-CD-CLuc 2.332 2.691 3.219 
HLCS-NLuc+N-CoR-CT-CLuc 10.094 12.725 12.853 
HLCS-NLuc+HDAC1-CLuc 8.229 10.628 9.420 
HLCS-NLuc+HDAC1Δ31-CLuc 8.355 9.737 9.383 
NLuc+CLuc 2.836 3.631 3.157 
TP53-NLuc+MDM2-CLuc 7.748 8.391 9.805 
TP53-NLuc+CDK3-CLuc 3.047 4.326 4.316 
 
Table 2 (Chapter I) The enrichment of H3K9ac marks in loci coding for repeats and 
GAPDH in HLCS overexpression HEK293 cells and controls. 
Cell lines Gene loci 
RT-PCR Ct values normalized by H3 and input 
1 2 3 
FLAG/Myc-HLCS LTR15 0.0528 0.0531 0.0545 
Control LTR15 0.1050 0.1083 0.1093 
FLAG/Myc-HLCS LTR22 0.3198 0.2877 0.3179 
Control LTR22 0.9610 0.9876 0.9598 
FLAG/Myc-HLCS Chr1apha 0.0093 0.0094 0.0098 
Control Chr1apha 0.0244 0.0248 0.0254 
FLAG/Myc-HLCS Chr4apha 0.0251 0.0261 0.0260 
Control Chr4apha 0.0496 0.0513 0.0528 
FLAG/Myc-HLCS GAPDH 0.7652 0.7054 0.7346 
Control GAPDH 0.7143 0.7049 0.7391 
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Table 3 (Chapter I) The abundance of transcripts coding for HLCS, LTRs, Chr1alpha, 
and Chr4alpha in HLCS overexpression HEK293 cells and controls. 
Cell lines Gene loci 
RT-PCR Ct values normalized by GAPDH 
1 2 3 
FLAG/Myc-HLCS HLCS 48.889 45.384 53.521 
Control HLCS 0.987 1.023 0.990 
FLAG/Myc-HLCS U5 0.181 0.175 0.165 
Control U5 0.991 1.011 0.998 
FLAG/Myc-HLCS R-U5 0.142 0.152 0.213 
Control R-U5 1.016 1.105 0.891 
FLAG/Myc-HLCS Chr1apha 0.215 0.194 0.173 
Control Chr1apha 1.107 0.878 1.029 
FLAG/Myc-HLCS Chr4apha 0.183 0.164 0.193 
Control Chr4apha 0.944 0.978 1.084 
  
112 
 
Table 4 (Chapter II) Effects of riboflavin concentrations in HepG2 cell culture media on 
glutathione reductase activity. 
Riboflavin 
Glutathione reductase activity [A340/(0.5 mg protein x 10 min)] 
1 2 3 
Deficient 0.211 0.198 0.191 
Sufficient 0.225 0.211 0.205 
Supplemented 0.351 0.319 0.343 
 
Table 5 (Chapter II) Effects of riboflavin concentrations in HepG2 cell culture media on 
reduced glutathione concentration. 
Riboflavin 
Reduced glutathione concentration (ug/2mg protein) 
1 2 3 
Deficient 49.733 51.067 50.867 
Sufficient 59.267 60.000 60.867 
Supplemented 60.733 61.533 62.200 
 
Table 6 (Chapter II) Effects of riboflavin concentrations in HepG2 cell culture media on 
LSD demethylase activity. 
Riboflavin 
LSD demethylase activity (arbitrary units)
1 2 3 
Deficient 2.877 3.800 3.610 
Sufficient 3.384 3.850 4.182 
Supplemented 4.479 4.538 4.792 
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Table 7 (Chapter II) Effects of riboflavin concentrations in HepG2 cell culture media on 
expression of LSD1 and albumin mRNA. 
Riboflavin 
RT-PCR Ct values normalized by GAPDH 
LSD1 Albumin 
1 2 3 1 2 3 
Deficient 1.237 1.315 1.293 2.925 3.047 3.101 
Sufficient 1.021 0.998 0.981 0.940 0.977 1.089 
Supplemented 1.072 1.019 0.901 0.944 0.842 1.093 
 
Table 8 (Chapter II) Effects of riboflavin concentrations in HepG2 cell culture media on 
the enrichment of LSD1, H3K4me2, and H3K9me3 in the albumin promoter. 
Riboflavin 
RT-PCR Ct values 
normalized by H3 and 
input 
LSD1 
1 2 3 
Deficient 1.257 1.306 1.561 
Sufficient 0.905 0.585 0.612 
Supplemented 0.896 0.486 0.768 
Riboflavin 
RT-PCR Ct values normalized by H3 and input 
H3K4me2 H3K9me3 
1 2 3 1 2 3 
Deficient 3.502 3.386 3.327 0.337 0.299 0.302 
Sufficient 1.255 1.235 1.213 0.485 0.519 0.500 
Supplemented 1.042 1.063 1.017 0.468 0.469 0.531 
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Table 9 (Chapter III) Effects of riboflavin concentrations in Jurkat cell culture media on 
glutathione reductase activity. 
Riboflavin 
Glutathione reductase activity [A340/(0.5 mg protein x 10 min)] 
1 2 3 
Deficient 0.210 0.213 0.189 
Sufficient 0.227 0.215 0.208 
Supplemented 0.274 0.252 0.271 
 
Table 10 (Chapter III) Effects of riboflavin concentrations in Jurkat cell culture media on 
reduced glutathione concentration. 
Riboflavin 
Reduced glutathione concentration (ug/mg protein) 
1 2 3 
Deficient 26.133 26.200 26.667 
Sufficient 32.633 32.467 33.233 
Supplemented 32.700 33.133 33.300 
 
Table 11 (Chapter III) Effects of riboflavin concentrations in Jurkat cell culture media on 
LSD demethylase activity. 
Riboflavin 
LSD demethylase activity (arbitrary units)
1 2 3 
Deficient 3.532 3.086 3.791 
Sufficient 3.304 3.032 4.121 
Supplemented 5.051 4.258 4.571 
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Table 12 (Chapter III) Effects of riboflavin concentrations in Jurkat cell culture media on 
the expression of LSD1 and pro-inflammatory cytokine mRNA. 
Riboflavin 
RT-PCR Ct values 
normalized by GAPDH 
LSD1 
1 2 3 
Deficient 1.011 1.009 0.980 
Sufficient 0.640 0.636 0.638 
Supplemented 0.481 0.482 0.485 
Riboflavin 
RT-PCR Ct values normalized by GAPDH 
IL-1α IL-1β 
1 2 3 1 2 3 
Deficient 1.021 0.998 0.981 1.065 1.067 0.880 
Sufficient 0.644 0.557 0.559 0.158 0.158 0.199 
Supplemented 0.516 0.544 0.484 0.072 0.094 0.087 
Riboflavin 
RT-PCR Ct values normalized by GAPDH 
IL-6 TNF-α 
1 2 3 1 2 3 
Deficient 0.868 1.248 0.923 1.008 1.028 0.965 
Sufficient 0.613 0.560 0.698 0.514 0.509 0.454 
Supplemented 0.450 0.491 0.460 0.438 0.394 0.379 
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Table 13 (Chapter III) Effects of riboflavin concentrations in Jurkat cell culture media on 
the enrichment of H3K4me2 marks in pro-inflammatory gene promoter and exon 1. 
 Riboflavin 
RT-PCR Ct values normalized by H3 and input
1 2 3 4 5 
IL-1α 
promoter 
Deficient 0.284 0.209 0.297 0.218 0.198 
Sufficient 0.180 0.187 0.136 0.168 0.171 
Supplemented 0.205 0.193 0.205 0.209 0.283 
exon 1 
Deficient 2.781 2.208 2.700 1.830 2.061 
Sufficient 0.755 1.141 0.983 0.871 1.146 
Supplemented 0.852 0.909 1.207 0.947 0.892 
IL-1β 
promoter 
Deficient 0.353 0.415 0.431 0.374 0.381 
Sufficient 0.321 0.317 0.377 0.297 0.343 
Supplemented 0.326 0.378 0.375 0.377 0.405 
exon 1 
Deficient 0.832 0.949 0.950 0.888 0.890 
Sufficient 0.637 0.597 0.589 0.613 0.599 
Supplemented 0.554 0.569 0.638 0.621 0.532 
IL-6 
promoter 
Deficient 1.344 1.323 1.308 1.306 1.349 
Sufficient 1.122 1.158 1.121 1.234 1.371 
Supplemented 1.224 1.147 1.219 1.211 1.304 
exon 1 
Deficient 13.038 12.132 13.297 11.319 13.757 
Sufficient 10.049 8.397 9.809 11.030 10.763 
Supplemented 9.075 10.295 9.922 9.235 9.129 
TNF- α 
promoter 
Deficient 0.230 0.195 0.249 0.215 0.285 
Sufficient 0.179 0.149 0.208 0.141 0.153 
Supplemented 0.232 0.214 0.189 0.239 0.230 
exon 1 
Deficient 16.539 16.152 15.795 15.904 15.688 
Sufficient 14.514 15.272 15.172 12.712 14.425 
Supplemented 11.805 11.845 12.271 11.942 11.720 
 
